US20230190664A1 - Crosslinked particles - Google Patents
Crosslinked particles Download PDFInfo
- Publication number
- US20230190664A1 US20230190664A1 US17/871,339 US202217871339A US2023190664A1 US 20230190664 A1 US20230190664 A1 US 20230190664A1 US 202217871339 A US202217871339 A US 202217871339A US 2023190664 A1 US2023190664 A1 US 2023190664A1
- Authority
- US
- United States
- Prior art keywords
- crosslinked
- particle
- particles
- drug
- shows
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002245 particle Substances 0.000 title claims abstract description 273
- 239000011859 microparticle Substances 0.000 claims abstract description 140
- 239000003814 drug Substances 0.000 claims abstract description 104
- 229940079593 drug Drugs 0.000 claims abstract description 100
- 229920000728 polyester Polymers 0.000 claims abstract description 96
- 239000002105 nanoparticle Substances 0.000 claims abstract description 22
- 229920000642 polymer Polymers 0.000 claims description 61
- 229920001223 polyethylene glycol Polymers 0.000 claims description 40
- 239000002202 Polyethylene glycol Substances 0.000 claims description 39
- TZIZWYVVGLXXFV-FLRHRWPCSA-N Triamcinolone hexacetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@@H]2O TZIZWYVVGLXXFV-FLRHRWPCSA-N 0.000 claims description 35
- 229960004221 triamcinolone hexacetonide Drugs 0.000 claims description 35
- 229920001610 polycaprolactone Polymers 0.000 claims description 31
- 239000004632 polycaprolactone Substances 0.000 claims description 31
- 229930012538 Paclitaxel Natural products 0.000 claims description 27
- 229960001592 paclitaxel Drugs 0.000 claims description 27
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 27
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 20
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 20
- 239000000178 monomer Substances 0.000 claims description 15
- 150000001408 amides Chemical class 0.000 claims description 14
- 150000003852 triazoles Chemical class 0.000 claims description 13
- 150000003568 thioethers Chemical class 0.000 claims description 12
- 229920000954 Polyglycolide Polymers 0.000 claims description 8
- 239000004633 polyglycolic acid Substances 0.000 claims description 8
- 239000004626 polylactic acid Substances 0.000 claims description 7
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 6
- 229960005294 triamcinolone Drugs 0.000 claims description 6
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 6
- 150000002596 lactones Chemical class 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 abstract description 65
- 238000001356 surgical procedure Methods 0.000 abstract description 7
- 238000001727 in vivo Methods 0.000 abstract description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 74
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 68
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 67
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 60
- 229910001868 water Inorganic materials 0.000 description 57
- 239000004971 Cross linker Substances 0.000 description 51
- 238000000034 method Methods 0.000 description 45
- 239000000203 mixture Substances 0.000 description 45
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 37
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 description 35
- 229940109262 curcumin Drugs 0.000 description 34
- 235000012754 curcumin Nutrition 0.000 description 34
- 239000004148 curcumin Substances 0.000 description 34
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 34
- 125000000524 functional group Chemical group 0.000 description 33
- 239000002904 solvent Substances 0.000 description 32
- 239000000839 emulsion Substances 0.000 description 29
- 239000000243 solution Substances 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 27
- 238000001000 micrograph Methods 0.000 description 27
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 24
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 23
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 23
- 239000004372 Polyvinyl alcohol Substances 0.000 description 21
- 229920002451 polyvinyl alcohol Polymers 0.000 description 21
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 21
- 238000002296 dynamic light scattering Methods 0.000 description 20
- 238000011068 loading method Methods 0.000 description 20
- -1 macroparticles Substances 0.000 description 20
- 150000004985 diamines Chemical class 0.000 description 16
- 239000003999 initiator Substances 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- 239000006184 cosolvent Substances 0.000 description 15
- 150000001336 alkenes Chemical group 0.000 description 14
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 150000003254 radicals Chemical class 0.000 description 14
- 229920001577 copolymer Polymers 0.000 description 13
- 239000003125 aqueous solvent Substances 0.000 description 12
- 239000003054 catalyst Substances 0.000 description 12
- 229920000136 polysorbate Polymers 0.000 description 11
- 239000004094 surface-active agent Substances 0.000 description 11
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 10
- 239000008273 gelatin Substances 0.000 description 10
- 229920000159 gelatin Polymers 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 108010010803 Gelatin Proteins 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 235000019322 gelatine Nutrition 0.000 description 9
- 235000011852 gelatine desserts Nutrition 0.000 description 9
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 8
- ALPIESLRVWNLAX-UHFFFAOYSA-N hexane-1,1-dithiol Chemical compound CCCCCC(S)S ALPIESLRVWNLAX-UHFFFAOYSA-N 0.000 description 8
- 230000002209 hydrophobic effect Effects 0.000 description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 8
- 229920000053 polysorbate 80 Polymers 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 125000003396 thiol group Chemical group [H]S* 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 125000002843 carboxylic acid group Chemical group 0.000 description 7
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 150000004662 dithiols Chemical class 0.000 description 7
- 239000000693 micelle Substances 0.000 description 7
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 7
- URYYVOIYTNXXBN-OWOJBTEDSA-N trans-cyclooctene Chemical compound C1CCC\C=C\CC1 URYYVOIYTNXXBN-OWOJBTEDSA-N 0.000 description 7
- KWVGIHKZDCUPEU-UHFFFAOYSA-N 2,2-dimethoxy-2-phenylacetophenone Chemical compound C=1C=CC=CC=1C(OC)(OC)C(=O)C1=CC=CC=C1 KWVGIHKZDCUPEU-UHFFFAOYSA-N 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 125000003700 epoxy group Chemical group 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000001804 emulsifying effect Effects 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 150000002576 ketones Chemical class 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000000206 photolithography Methods 0.000 description 5
- 238000002791 soaking Methods 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- SRZXCOWFGPICGA-UHFFFAOYSA-N 1,6-Hexanedithiol Chemical compound SCCCCCCS SRZXCOWFGPICGA-UHFFFAOYSA-N 0.000 description 4
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 4
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 230000000269 nucleophilic effect Effects 0.000 description 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 4
- 238000006268 reductive amination reaction Methods 0.000 description 4
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 4
- 238000006596 Alder-ene reaction Methods 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- RXLFUOTZAXSVJO-TYYBGVCCSA-N C1=CN=NN=N1.C1CCC\C=C\CC1 Chemical compound C1=CN=NN=N1.C1CCC\C=C\CC1 RXLFUOTZAXSVJO-TYYBGVCCSA-N 0.000 description 3
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000006352 cycloaddition reaction Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical class CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000008143 Bone Morphogenetic Protein 2 Human genes 0.000 description 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000010640 amide synthesis reaction Methods 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229920000469 amphiphilic block copolymer Polymers 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 125000004427 diamine group Chemical group 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 150000002118 epoxides Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 2
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000007348 radical reaction Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- BUHVIAUBTBOHAG-FOYDDCNASA-N (2r,3r,4s,5r)-2-[6-[[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC1=CC(OC)=CC(C(CNC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=2C(=CC=CC=2)C)=C1 BUHVIAUBTBOHAG-FOYDDCNASA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- PRBHEGAFLDMLAL-UHFFFAOYSA-N 1,5-Hexadiene Natural products CC=CCC=C PRBHEGAFLDMLAL-UHFFFAOYSA-N 0.000 description 1
- TWZKQKDQTJYLSV-UHFFFAOYSA-N 4,4-bis(3-aminopropyl)heptane-1,7-diamine Chemical compound NCCCC(CCCN)(CCCN)CCCN TWZKQKDQTJYLSV-UHFFFAOYSA-N 0.000 description 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical class [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 238000006117 Diels-Alder cycloaddition reaction Methods 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- NSFFHOGKXHRQEW-UHFFFAOYSA-N Thiostrepton B Natural products N1C(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC(=O)C(C(C)CC)NC(C(C2=N3)O)C=CC2=C(C(C)O)C=C3C(=O)OC(C)C(C=2SC=C(N=2)C2N=3)NC(=O)C(N=4)=CSC=4C(C(C)(O)C(C)O)NC(=O)C(N=4)CSC=4C(=CC)NC(=O)C(C(C)O)NC(=O)C(N=4)=CSC=4C21CCC=3C1=NC(C(=O)NC(=C)C(=O)NC(=C)C(N)=O)=CS1 NSFFHOGKXHRQEW-UHFFFAOYSA-N 0.000 description 1
- 125000002355 alkine group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 238000010462 azide-alkyne Huisgen cycloaddition reaction Methods 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 1
- 229960002470 bimatoprost Drugs 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- LWVRJZXYUQBNHW-UHFFFAOYSA-N disulfide(2-) Chemical compound [S-][S-] LWVRJZXYUQBNHW-UHFFFAOYSA-N 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000007787 electrohydrodynamic spraying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- PYGSKMBEVAICCR-UHFFFAOYSA-N hexa-1,5-diene Chemical compound C=CCCC=C PYGSKMBEVAICCR-UHFFFAOYSA-N 0.000 description 1
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000001451 organic peroxides Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical class CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 239000012026 peptide coupling reagents Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000045 pyrolysis gas chromatography Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000007342 radical addition reaction Methods 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 150000003283 rhodium Chemical class 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 1
- 229950000055 seliciclib Drugs 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- NSFFHOGKXHRQEW-AIHSUZKVSA-N thiostrepton Chemical compound C([C@]12C=3SC=C(N=3)C(=O)N[C@H](C(=O)NC(/C=3SC[C@@H](N=3)C(=O)N[C@H](C=3SC=C(N=3)C(=O)N[C@H](C=3SC=C(N=3)[C@H]1N=1)[C@@H](C)OC(=O)C3=CC(=C4C=C[C@H]([C@@H](C4=N3)O)N[C@H](C(N[C@@H](C)C(=O)NC(=C)C(=O)N[C@@H](C)C(=O)N2)=O)[C@@H](C)CC)[C@H](C)O)[C@](C)(O)[C@@H](C)O)=C\C)[C@@H](C)O)CC=1C1=NC(C(=O)NC(=C)C(=O)NC(=C)C(N)=O)=CS1 NSFFHOGKXHRQEW-AIHSUZKVSA-N 0.000 description 1
- 229930188070 thiostrepton Natural products 0.000 description 1
- 229940063214 thiostrepton Drugs 0.000 description 1
- NSFFHOGKXHRQEW-OFMUQYBVSA-N thiostrepton A Natural products CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]4NC(=O)c5csc(n5)[C@@H](NC(=O)[C@H]6CSC(=N6)C(=CC)NC(=O)[C@@H](NC(=O)c7csc(n7)[C@]8(CCC(=N[C@@H]8c9csc4n9)c%10nc(cs%10)C(=O)NC(=C)C(=O)NC(=C)C(=O)N)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)[C@](C)(O)[C@@H](C)O)[C@H](C)O NSFFHOGKXHRQEW-OFMUQYBVSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 1
- 229960002368 travoprost Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Definitions
- the present disclosure teaches crosslinked particles (e.g., microparticles or nanoparticles) that are capable of storing and releasing drugs.
- the particles can release drug by degradation, erosion, diffusion, or a combination of mechanisms.
- Drug-eluting biodegradable nanoparticles can be used for a variety of biological applications, such as wound healing and arthritis treatment (see e.g., U.S. Pat. No. 7,935,782 and WO 2009/061854, the entire contents of which are hereby incorporated by reference in their entirety).
- wound healing and arthritis treatment see e.g., U.S. Pat. No. 7,935,782 and WO 2009/061854, the entire contents of which are hereby incorporated by reference in their entirety.
- previous attempts to produce crosslinked particles were limited in size and therefore could only be loaded with a limited amount of a given drug. Smaller particles also tended to biodegrade more quickly than larger particles, and were therefore unable to provide sustained release of for a desired duration.
- current drug delivery particles can suffer from a burst effect, wherein a substantial portion of a drug dispersed therein is released quickly released in a short period followed by a lower release rate. This has the effect of initially over dosing a patient and then later under dosing the patient.
- the present disclosure teaches particles (e.g., microparticles) that are crosslinked and can be used in vivo.
- the crosslinked particles can include a drug, and can release the drug when used in vivo. In some embodiments, the drug is released as the particle degrades.
- the microparticles can thus be used to release drugs at the site of wounds, or after surgical procedures to release therapeutic agents and help speed recovery.
- the particles of the current disclosure can be used for the treatment of arthritis. For example, particles comprising arthritis therapeutics can be administered to the site of arthritis pain (e.g., by injection).
- the present disclosure provides crosslinked particles such as microparticles that have reproducible size and morphology.
- the present disclosure also provides particles that can release a drug for a sustained period of time (e.g., greater than one month) and which do not suffer from a burst effect (e.g., a release of substantial amount of drug soon after immersion in a solvent).
- a sustained period of time e.g., greater than one month
- a burst effect e.g., a release of substantial amount of drug soon after immersion in a solvent
- the present disclosure provides a crosslinked degradable particle, comprising:
- polyester backbones wherein the plurality of polyester backbones are crosslinked via thioethers, triazoles, or amides; and a drug dispersed within the crosslinked degradable particle.
- the present disclosure provides a crosslinked degradable particle, comprising:
- the crosslinked degradable particle has a nominal diameter between 1 ⁇ m and 100 ⁇ m.
- the present disclosure provides a crosslinked degradable particle, comprising:
- a plurality of polymer backbones obtained from lactone monomer residues, wherein the plurality of polymer backbones are crosslinked via thioethers, triazoles, or amides; and a drug dispersed within the crosslinked degradable particle, wherein the crosslinked degradable particle has a nominal diameter between 1 micron and 100 microns.
- the present disclosure provides a method of preparing a crosslinked degradable particle, comprising:
- the present disclosure provides a method of preparing a crosslinked degradable particle, comprising:
- the present disclosure provides a method of preparing a crosslinked degradable particle, comprising:
- the present disclosure provides method of preparing a crosslinked degradable particle, comprising:
- the present disclosure provides a method of preparing a crosslinked degradable particle, comprising:
- the present disclosure provides a method of reducing aggregation of a plurality of crosslinked degradable particles, comprising attaching a plurality of polyethylene glycol chains to an exterior of the plurality of crosslinked degradable particles.
- the present disclosure provides a method of dispersing a drug within a crosslinked degradable particle, comprising:
- the present disclosure provides a method of preparing a crosslinked degradable implant, comprising:
- the present disclosure provides a method of controlling an average size of a distribution of crosslinked degradable particles, comprising:
- the present disclosure provides a method of controlling an average size of a distribution of crosslinked degradable particles, comprising:
- a polyester containing a plurality of functional groups and a crosslinker in at least one nonaqueous solvent to form an emulsion wherein the nonaqueous solvent comprises droplets of uniform size, wherein the polyester and crosslinker, are dissolved in the nonaqueous solvent droplets; and treating the emulsion to react the crosslinker with two of the functional groups to form a crosslink, wherein the particles are crosslinked while dissolved in the nonaqueous solvent.
- the present disclosure provides a crosslinked degradable particle, formed by:
- the present disclosure provides a method of treating a disease, comprising:
- the present disclosure provides use of a crosslinked degradable particle of the present disclosure for the treatment of a disease.
- the crosslinked particle contains a drug.
- the present disclosure provides the use of a crosslinked degradable particle of the present disclosure in the manufacture of a medicament for the treatment of a disease.
- the crosslinked particle contains a drug.
- the present disclosure provides a crosslinked degradable particle, comprising:
- R 1 is independently, at each occurrence, —H, or —C 1 -C 6 alkyl
- R 2 is independently, at each occurrence, —H, or —C 1 -C 6 alkyl
- R 3 is independently, at each occurrence, —H, or —C 1 -C 6 alkyl
- a is 0, 1, or 2
- m is independently, at each occurrence, an integer between 1 and 1000, inclusive
- n is independently, at each occurrence, an integer between 1 and 1000, inclusive
- p is independently, at each occurrence, an integer between 0 and 5, inclusive
- q is independently, at each occurrence, an integer between 0 and 1000, inclusive
- r is independently, at each occurrence, an integer between 0 and 1000, inclusive
- t is independently, at each occurrence, an integer between 0 and 5, inclusive.
- the present disclosure provides a crosslinked degradable particle
- R 1 is independently, at each occurrence, —H, or —C 1 -C 6 alkyl
- R 2 is independently, at each occurrence, —H, or —C 1 -C 6 alkyl
- R 3 is independently, at each occurrence, —H, or —C 1 -C 6 alkyl
- a is 0, 1, or 2
- m is independently, at each occurrence, an integer between 1 and 1000, inclusive
- n is independently, at each occurrence, an integer between 1 and 1000, inclusive
- p is independently, at each occurrence, an integer between 0 and 5, inclusive
- q is independently, at each occurrence, an integer between 0 and 1000, inclusive
- r is independently, at each occurrence, an integer between 0 and 1000, inclusive
- t is independently, at each occurrence, an integer between 0 and 5, inclusive.
- the present disclosure provides a crosslinked degradable particle
- R 1 is independently, at each occurrence, —H, or —C 1 -C 6 alkyl
- R 2 is independently, at each occurrence, —H, or —C 1 -C 6 alkyl
- R 3 is independently, at each occurrence, —H, or —C 1 -C 6 alkyl
- a is 0, 1, or 2
- m is independently, at each occurrence, an integer between 1 and 1000, inclusive
- n is independently, at each occurrence, an integer between 1 and 1000, inclusive
- p is independently, at each occurrence, an integer between 0 and 5, inclusive
- q is independently, at each occurrence, an integer between 0 and 1000, inclusive
- r is independently, at each occurrence, an integer between 0 and 1000, inclusive
- t is independently, at each occurrence, an integer between 0 and 5, inclusive.
- the present disclosure provides a crosslinked degradable particle
- R 1 is independently, at each occurrence, —H, or —C 1 -C 6 alkyl
- R 2 is independently, at each occurrence, —H, or —C 1 -C 6 alkyl
- R 3 is independently, at each occurrence, —H, or —C 1 -C 6 alkyl
- a is 0, 1, or 2
- m is independently, at each occurrence, an integer between 1 and 1000, inclusive
- n is independently, at each occurrence, an integer between 1 and 1000, inclusive
- p is independently, at each occurrence, an integer between 0 and 5, inclusive
- q is independently, at each occurrence, an integer between 0 and 1000, inclusive
- r is independently, at each occurrence, an integer between 0 and 1000, inclusive
- t is independently, at each occurrence, an integer between 0 and 5, inclusive.
- the present disclosure provides a crosslinked degradable particle, a polyester backbone of the Formula V:
- R 1 is independently, at each occurrence, —H, or —C 1 -C 6 alkyl
- R 2 is independently, at each occurrence, —H, or —C 1 -C 6 alkyl
- R 3 is independently, at each occurrence, —H, or —C 1 -C 6 alkyl
- a is 0, 1, or 2
- m is independently, at each occurrence, an integer between 1 and 1000, inclusive
- n is independently, at each occurrence, an integer between 1 and 1000, inclusive
- p is independently, at each occurrence, an integer between 0 and 5, inclusive
- q is independently, at each occurrence, an integer between 0 and 1000, inclusive
- r is independently, at each occurrence, an integer between 0 and 1000, inclusive
- t is independently, at each occurrence, an integer between 0 and 5, inclusive.
- the present disclosure provides a crosslinked degradable particle, comprising:
- R 1 is independently, at each occurrence, —H, or —C 1 -C 6 alkyl
- R 2 is independently, at each occurrence, —H, or —C 1 -C 6 alkyl
- R 3 is independently, at each occurrence, —H, or —C 1 -C 6 alkyl
- a is 0, 1, or 2
- m is independently, at each occurrence, an integer between 1 and 1000, inclusive
- n is independently, at each occurrence, an integer between 1 and 1000, inclusive
- p is independently, at each occurrence, an integer between 0 and 5, inclusive
- q is independently, at each occurrence, an integer between 0 and 1000, inclusive
- r is independently, at each occurrence, an integer between 0 and 1000, inclusive
- t is independently, at each occurrence, an integer between 0 and 5, inclusive.
- the present disclosure provides a crosslinked degradable particle, comprising:
- R is independently, at each occurrence, —H, or —C 1 -C 6 alkyl
- R 1 is independently, at each occurrence, —H, or —C 1 -C 6 alkyl
- R 2 is independently, at each occurrence, —H, or —C 1 -C 6 alkyl
- R 3 is independently, at each occurrence, —H, or —C 1 -C 6 alkyl
- a is 0, 1, or 2
- m is independently, at each occurrence, an integer between 1 and 1000, inclusive
- n is independently, at each occurrence, an integer between 1 and 1000, inclusive
- p is independently, at each occurrence, an integer between 0 and 5, inclusive
- q is independently, at each occurrence, an integer between 0 and 1000, inclusive
- r is independently, at each occurrence, an integer between 0 and 1000, inclusive
- t is independently, at each occurrence, an integer between 0 and 5, inclusive.
- the crosslinked particles (e.g., macroparticles, microparticles or nanoparticles) of the present disclosure can have uniform size and shape along with other characteristics such as stability. This can allow the crosslinked particles of the present disclosure to be used in medical settings with high reproducibility and reliability. Additional features and advantages of the present disclosure will be apparent to one of skill in the art and are set forth in the Detailed Description, below.
- FIG. 1 A shows a photo of polycaprolactone (PCL), polyvalerolactone/polyallylvalerolactone copolymer (PVL-co-PAVL) microparticles at a scale of about 1500 ⁇ m.
- PCL polycaprolactone
- PVL-co-PAVL polyvalerolactone/polyallylvalerolactone copolymer
- FIG. 1 B shows photo of PCL, PVL-co-PAVL microparticles at a scale of about 400 ⁇ m.
- FIG. 1 C shows a photo of PCL, PVL-co-PAVL microparticles at a scale of about 600 ⁇ m.
- FIG. 1 D shows a photo of PCL, PVL-co-PAVL microparticles at a scale of about 20 ⁇ m, along with a size distribution scheme.
- FIG. 2 A shows a photo of PVL-co-PAVL microparticles at a scale of about 1500 ⁇ m.
- FIG. 2 B shows photo of PVL-co-PAVL microparticles at a scale of about 400 ⁇ m.
- FIG. 2 C shows a photo of PVL-co-PAVL microparticles at a scale of about 600 ⁇ m.
- FIG. 2 D shows a photo of PVL-co-PAVL microparticles at a scale of about 20 ⁇ m, along with a size distribution scheme.
- FIG. 3 A shows a schematic of self-assembly of amphiphilic block copolymers into micellar structures.
- FIG. 3 B shows a schematic of encapsulation of polymers and crosslinkers of the present disclosure into the lipid phase of a lipid-water emulsion.
- FIG. 4 shows a general schematic for loading drugs into particles of the present disclosure
- FIG. 5 shows a DLS plot of crosslinked mPEG-b-PVL-co-PAVL nanoparticles in water.
- FIG. 6 shows a DLS plot of crosslinked mPEG-b-PVL-co-PAVL nanoparticles in dimethylsulfoxide (DMSO).
- FIG. 7 shows a DLS plot of crosslinked mPEG-b-PVL-co-PAVL nanoparticles in THF.
- FIG. 8 shows a DLS plot of non-crosslinked mPEG-b-PVL-co-PAVL nanoparticles in water.
- FIG. 9 A shows a histogram and an image of 25% PVL-co-PAVL microparticles after crosslinking.
- FIG. 9 B shows a histogram and microscope image of the same microparticles after a DMSO washing step.
- FIG. 9 C shows a histogram and microscope image of the particles after an ethanol washing step.
- FIG. 9 D shows a histogram and microscope image of the particles after swelling in THF.
- FIG. 10 A shows a 1 HNMR spectrum of PVL-co-PAVL polymer.
- FIG. 10 B shows a gel permeation chromatography plot of the PVL-co-PAVL polymer backbone comprising 6% PAVL, 10% PAVL, and 25% PAVL.
- FIG. 11 A shows a microscope image of mPEG-b-PVL-co-PAVL macroparticles (80:20) at a resolution of about 1 mm.
- FIG. 11 B shows a microscope image of mPEG-b-PVL-co-PAVL macroparticles (80:20) at a resolution of about 200 ⁇ m.
- FIG. 11 C shows a first microscope image of mPEG-b-PVL-co-PAVL macroparticles (80:20) at a resolution of about 10 ⁇ m.
- FIG. 11 D shows a second microscope image of mPEG-b-PVL-co-PAVL macroparticles (80:20) at a resolution of about 10 ⁇ m.
- FIG. 12 shows a microscope micrograph of non-crosslinked microparticles in water.
- FIG. 13 shows the drug loading capacity of macroparticles, according to an embodiment of the disclosure.
- FIG. 14 shows a DSC plot of microparticles loaded with curcumin, paclitaxel, triamcinolone acetonide, triamcinolone hexacetonide, and without drug.
- FIG. 15 shows FTIR spectra of microparticles of the present disclosure loaded with curcumin, paclitaxel, triamcinolone acetonide, triamcinolone hexacetonide, and without drug.
- FIG. 16 shows a microscopic image of microparticle flakes after being dried overnight.
- FIG. 17 shows the release profile of curcumin release from microparticle flakes.
- FIG. 18 A shows curcumin-loaded particles dissolved in water containing 1% tween after being dried in THF with 25% PEG as a co-solvent.
- FIG. 18 B shows a close-up view of curcumin-loaded particles dissolved in water containing 1% tween after being dried in THF with 25% PEG as a co-solvent.
- FIG. 19 A shows a microscope image of microparticle flakes in water after drying with 2.5% PEG as a co-solvent.
- FIG. 19 B shows a microscope image of microparticle flakes in THF after drying with 2.5% PEG as a co-solvent.
- FIG. 19 C shows a microscope image of microparticle flakes in water after drying with 5% PEG as a co-solvent.
- FIG. 19 D shows a microscope image of microparticle flakes in THF after drying with 5% PEG as a co-solvent.
- FIG. 20 A shows an aqueous solubility plot of triamcinolone acetonide in the presence of surfactants Tween 80 and SDS.
- FIG. 20 B shows an aqueous solubility plot of triamcinolone hexacetonide in the presence of surfactants Tween 80 and SDS.
- FIG. 20 C shows an aqueous solubility plot of paclitaxel in the presence of surfactants Tween 80 and SDS.
- FIG. 21 shows a 7-day release profile of curcumin from a macroparticle.
- FIG. 22 shows a 20-day curcumin release profile from a 13-mg and 12-mg macroparticle.
- FIG. 23 shows a 6-day release profile of triamcinolone hexacetonide from two macroparticles.
- FIG. 24 shows a 20-day triamcinolone hexacetonide release profile from a 13.3-mg and 9.2-mg macroparticle.
- FIG. 25 shows a comparison of the release profiles of curcumin, triamcinolone hexacetonide (TAH), triamcinolone acetonide (TAA), and paclitaxel (PTX).
- TH triamcinolone hexacetonide
- TAA triamcinolone acetonide
- PTX paclitaxel
- FIG. 26 shows a microscope micrograph of the photolithography template.
- FIG. 27 A shows a gelatin template with raised pegs under a microscope.
- FIG. 27 B shows a first microscope image of microparticles prepared by the gelatin hydrogel template method.
- FIG. 27 C shows a second microscope image of microparticles prepared by the gelatin hydrogel template method.
- FIG. 28 A shows a DSC plot of a control microparticle with no crosslinking.
- FIG. 28 B shows a DSC plot of a microparticle with 50% crosslinking.
- the DSC plot shows about 30% of crystallinity.
- FIG. 28 C shows a DSC plot of a microparticle with 100% crosslinking.
- FIG. 29 A shows a DSC plot of a control microparticle with no crosslinking.
- FIG. 29 B shows a DSC plot of a microparticle with 50% crosslinking.
- the DSC plot shows less than 1% crystallinity.
- FIG. 29 C shows a DSC plot with 100% crosslinking.
- the present disclosure provides crosslinked particles (e.g., microparticles, microparticles or nanoparticles) that can be used in medical applications (e.g., to locally release drugs).
- the present disclosure provides microparticles comprising a polyester backbone that can be crosslinked via functional groups disposed along the polyester backbone in the presence of an appropriate crosslinking reagent.
- the polyester backbones are crosslinked via thioethers.
- the polyester backbones can be crosslinked via triazoles.
- the polyester backbones can be crosslinked via amides.
- the polyester backbones can be crosslinked via amines (e.g., via an amine-epoxide reaction).
- the polyester backbones can be crosslinked by a tetrazine-trans-cyclooctene reaction.
- the polyester backbones can be crosslinked by a thiol-norbornene reaction.
- the polyester backbones can be crosslinked by an amine-carbonyl (e.g., aldehyde or ketone) reductive amination.
- the particles can be biodegradable.
- the microparticles of the present disclosure can have a diameter between about 1 ⁇ m and about 999 ⁇ m, including all ranges and subranges therebetween, and more preferably, the microparticles can have a diameter between about 1 ⁇ m and about 100 ⁇ m, including all ranges and subranges therebetween. In some embodiments, the microparticles of the present disclosure can have a diameter between about 5 ⁇ m and about 30 ⁇ m, including all ranges and subranges therebetween (e.g., between about 7 ⁇ m and about 15 ⁇ m or about 10 ⁇ m).
- the macroparticles of the present disclosure can have a mean diameter greater than about 1000 ⁇ m.
- the drug dispersed within a microparticle of the disclosure can be triamcinolone, triamcinolone acetonide, triamcinolone hexacetonide, and paclitaxel.
- other compounds such as curcumin can be dispersed within the particles (for instance, curcumin can be used to more easily visualize release kinetics).
- curcumin can be used as a surrogate for a drug.
- the drug is covalently bonded to the particle.
- the drug is contained within the particle by noncovalent interactions.
- the particle releases the drug over a period of at least one week in an aqueous environment (e.g., at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 2 months, at least 3 months, at least 4 months, at least 5 months, or at least 6 months). In some embodiments, the particle degrades as it releases the drug.
- the polyester backbone comprises polyvalerolactone (PVL), polycaprolactone (PCL), polylactic acid (PLA), polyglycolic acid (PGC), or a combination thereof.
- the particle is a macroparticle.
- the particle is a microparticle.
- the particle is a nanoparticle.
- the polyester backbone further comprises polyethylene glycol (PEG).
- the polymer backbone is obtained from a monomer residue comprising valerolactone (e.g., polyvalerolactone), caprolactone (e.g., polycaprolactone), lactic acid (e.g., polylactic acid), glycolic acid (e.g., polyglycolic acid), or a combination thereof.
- the lactone monomer is selected from the group consisting of lactic acid, glycolic acid, valerolactone, caprolactone, lactide, or a combination thereof.
- any of the valerolactone, caprolactone, lactic acid, lactide, or glycolic acid is functionalized with a functional group.
- the functional group can be selected from an allyl group, a propargyl group, or a carboxylic acid group (e.g., the functional groups can be allyl lactide, allyl valerolactone and the like).
- the functional group can be a trans-cyclooctene, norbornene, or a carbonyl group (e.g., an aldehyde or ketone).
- the functional group can be a thiol group, an amine, or a tetrazine.
- the polyester and crosslinker are combined in a solvent to form the mixture.
- particles of the disclosure are made by emulsifying the mixture, wherein the polyester and the crosslinker are in the same phase.
- the methods further comprise evaporating at least part of the solvent prior to reacting the functional groups with the crosslinker.
- the functional group of the polyester backbone comprises an olefin group (e.g., an allyl group), an alkynyl group (e.g., a propargyl group), an epoxy group, a carboxylic acid group, or a carboxylic acid derivative (e.g., an ester or amide).
- particles (e.g., microparticles) of the present disclosure can be formed by electrospraying. In some embodiments, particles (e.g., microparticles) of the present disclosure can be formed by spray-drying.
- the crosslinker comprises a dithiol group. In some embodiments, the dithiol group forms a thioether with an olefin functional group on the polyester backbone. In some embodiments, the crosslinker comprises a diazide. In some embodiments, the diazide forms a triazole with a propargyl functional group on the polyester backbone. In some embodiments, the crosslinker comprises a diamine. In some embodiments, diamine forms a ⁇ -hydroxy amine with an epoxide functional group on the polyester backbone. In some embodiments, the diamine forms an amide with a carboxylic acid functional group on the polyester backbone.
- the step of treating the emulsion comprises heating the emulsion or adding a catalyst (e.g., a cyclization catalyst such as a copper or rhodium salt such as a copper (I) salt).
- a catalyst e.g., a cyclization catalyst such as a copper or rhodium salt such as a copper (I) salt.
- the catalyst for forming an amide crosslinker is an amide coupling catalyst such as N,N′-dicyclohexylcarbodiimide or diisopropylcarbodiimide.
- the polyester backbones comprise polyvalerolactone, polycaprolactone, polylactic acid, polyglycolic acid, or a combination thereof. In some embodiments, the polyester backbones are crosslinked by thioethers, triazoles, or amides.
- the act of combining a polyester with a plurality of functional groups and a crosslinker can further comprise also adding an initiator (e.g., a photoinitiator) and/or a catalyst (e.g., a copper catalyst).
- an initiator e.g., a photoinitiator
- a catalyst e.g., a copper catalyst
- the solution e.g., the emulsion in which the particles are formed further comprises an initiator (e.g., a photoinitiator).
- the method of treating the solution comprises irradiating the photoinitiator with ultraviolet light.
- a dithiol group forms a thioether with an olefin functional group on the polyester backbone.
- the thioether is formed by a radical reaction.
- the radical reaction is initiated by a photoinitiator and treatment with ultraviolet light.
- the crosslinker comprises a diazide.
- the diazide forms a triazole with a propargyl functional group on the polyester backbone.
- the triazole is formed in the presence of a copper (I) catalyst.
- an element means one element or more than one element.
- Alkyl refers to a straight or branched chain saturated hydrocarbon.
- C 1 -C 6 alkyl groups contain 1 to 6 carbon atoms. Examples of a C 1 -C 6 alkyl group include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, isopropyl, isobutyl, sec-butyl and tert-butyl, isopentyl and neopentyl.
- treating refers to improving at least one symptom of the subject's disorder. Treating includes curing, improving, or at least partially ameliorating the disorder.
- disorder is used in this disclosure to mean, and is used interchangeably with, the terms disease, condition, or illness, unless otherwise indicated.
- administer refers to either directly administering a disclosed particle (e.g., a microparticle) or pharmaceutically acceptable salt of the disclosed particle or a composition to a subject.
- polyester backbone is understood to mean a polyester chain
- the polyester backbones of the present disclosure can be crosslinked to form particles such as microparticles or nanoparticles as disclosed herein.
- a “particle” is a discrete unit comprising polymer backbones as set forth herein that has been crosslinked.
- the particle can be a nanoparticle, a microparticle, or a macroparticle.
- the particle may include a drug dispersed therein.
- a “nanoparticle” is understood as a crosslinked particle of the present disclosure with a diameter of between about 1 nm and about 999 nm, including all size ranges and subranges therebetween.
- a “microparticle” as used herein is understood as a crosslinked particle of the present disclosure with a diameter of between about 1 ⁇ m (1,000 nm) and about 999 ⁇ m including all size ranges and subranges therebetween.
- the microparticles can have a diameter between about 1 ⁇ m and about 100 ⁇ m, including all ranges and subranges therebetween.
- the microparticles of the present disclosure can have a diameter between about 5 ⁇ m and about 30 ⁇ m, including all ranges and subranges therebetween (e.g., between about 7 ⁇ m and about 15 ⁇ m or about 10 ⁇ m).
- a “macroparticle” as used herein is understood as a crosslinked particle of the present disclosure with a diameter of between about 1 mm (1,000 ⁇ m) and about 100 mm, including all size ranges and subranges therebetween.
- a “macroparticle” can be a device or implant.
- a single macroparticle can be visible to the naked eye.
- macroparticles are referred to as “cylinders.”
- a “drug” is any small molecule therapeutic agent.
- a drug can be, without limitation, a steroid such as triamcinolone, triamcinolone acetonide, triamcinolone hexacetonide, or paclitaxel.
- a “drug” can also include a visualizing agent such as curcumin.
- a “patient” or “subject” is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon, or rhesus.
- Particles of the present disclosure can be used in medical applications.
- particles can be used to heal a wound (e.g., as antiseptics).
- a wound is understood as an injury to living tissue.
- Wounds can be caused by cuts, blows, or impacts. Wounds can also be the result of a surgery.
- the compounds of the present disclosure can be used to help heal wounds after a surgery.
- the particles of the present disclosure can be injected (e.g., with a syringe).
- the particles of the present disclosure are administered during a surgery and remain after the surgery (e.g., for a period of 1-6 months).
- crosslinking density of the particle is based on the percentage of the pendant functionality (e.g., allyl, propargyl, or epoxy) of the linear polymer precursor (e.g., polyester) (van der Ende, A. E., et al. (2008) J. Am Chem. Soc. 130, p. 8706).
- cross-linking density refers to the proportion of functionalized monomer (e.g., allyl valerolactone) used in preparing a polymer such as a copolymer, expressed as a weight percentage of monomers used.
- the crosslinking density of the resulting particle is understood to be 4%.
- Actual crosslinking density can be determined by analytical techniques including, but not limited to, infrared spectroscopy, pyrolysis gas chromatography, and nuclear magnetic resonance.
- the crosslinking densities of the particles of the present disclosure can be between 1% and 100%, inclusive. In some embodiments, the crosslinking density is about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%.
- VL valerolactone
- Microparticles of the present disclosure can be prepared by dissolution of functionalized polyesters in a solvent along with a crosslinker and subsequent crosslinking of the mixture.
- the resulting product is a plurality of crosslinked microparticles.
- microparticles comprising PCL with (polyallylvalerolactone-polyvalerolactone) PAVL-PVL (Example 3) and PAVL-PVL (Example 4) were crosslinked using hexanedithiol in the presence of 2,2-dimethoxy-2-phenylacetophenone (DMPA) by irradiation with ultraviolet (UV) light.
- DMPA 2,2-dimethoxy-2-phenylacetophenone
- DMSO dimethyl sulfoxide
- Comparative Examples 3 and 4 demonstrate microparticles that are produced in the absence of a crosslinker. Comparative Examples 3 and 4 combine PCL with PAVL-PVL (Comparative Example 3) and PAVL-PVL (Comparative Example 4) with UV light in the absence of a crosslinker (e.g., hexanedithiol). Because no crosslinking can occur in the absence of a crosslinker, no microparticles were formed. Accordingly, the polyesters remained intact and were soluble in DMSO. Therefore, in some embodiments, it is necessary to crosslink the polyesters described herein in order to form microparticles and in order to ensure desired characteristics such as stability and size.
- a crosslinker e.g., hexanedithiol
- polymer backbones that are incapable of crosslinking can be dependent upon micelle concentration in order to form.
- micelle concentration e.g., PLGA polymers
- amphiphilic block copolymers can self-assemble into micellar structures.
- micelles can fall apart below the critical micelle concentration (CMC).
- compounds of the present disclosure comprise functionalized polymers and reactive crosslinkers and are covalently crosslinked in a particle (e.g., nanoparticle or microparticle) structure.
- a particle e.g., nanoparticle or microparticle
- the particles of the present disclosure remain intact regardless of concentration and are not dependent upon the critical micelle concentration.
- the microparticles are crosslinked.
- Schemes 1 through 3 below show general routes to the crosslinked particles of the present disclosure.
- a polyester comprising polyvalerolactone and polyallylvalerolactone (1) can be crosslinked in using a disulfide (2) in the presence of a radical initiator (e.g., a photoinitiator such as DMPA).
- a radical initiator e.g., a photoinitiator such as DMPA
- the ratio of DMPA per allyl group can be adjusted to control the properties of the resulting microparticle (e.g., to produce more or less crosslinking). For instance, in some embodiments 0.2 equivalents of DMPA per allyl group can be added.
- one thiol group in (2) can be added for each allyl group in (1).
- the allyl groups can crosslink with the thiol groups of the crosslinker to produce a crosslinked microparticle (3).
- UV light e.g., 365 nm
- the values for d, e, and f can each independently be any integer between 1 and 1000, inclusive.
- a polyester comprising polyvalerolactone and polyallylvalerolactone (4) can be crosslinked in using a disulfide (5) in the presence of a radical initiator (e.g., a photoinitiator such as DMPA).
- a radical initiator e.g., a photoinitiator such as DMPA
- the ratio of DMPA to allyl groups can be adjusted to control the properties of the resulting microparticle (e.g., to adjust the rate of crosslinking and to produce more or less crosslinking). For instance, in some embodiments 0.2 equivalents of DMPA per allyl group can be added.
- one thiol group in (5) can be added for each allyl group in (4).
- the allyl groups can crosslink with the thiol groups of the crosslinker to produce a crosslinked microparticle (6).
- the values for d, e, and f can each independently be any integer between 1 and 1000, inclusive.
- crosslinking can take place by the reaction of an amine group with a carbonyl (e.g., a reductive amination).
- a polymer backbone functionalized with carbonyl groups e.g., aldehydes or ketones such as methyl ketones
- a reducing agent e.g., sodium cyanoborohydride
- an acid e.g., acetic acid
- Scheme 3 shows a reductive amination between a diamine (8) and a polymer backbone that is functionalized with an aldehyde and a methyl ketone (7) to produce a crosslinked polymer (9).
- a crosslinking reductive amination using, for instance, only aldehydes, or only ketones (e.g., phenyl ketones, ethyl ketones, and the like), or a mixture of both aldehydes and ketones.
- the variables d, e, and f can be integers between 1 and 1000, inclusive.
- the microparticles of the present disclosure can be made from functionalized polymer backbones. That is, as set forth below, the polymer backbones can be functionalized with, for instance, olefin (e.g., allyl), alkynyl (e.g., propargyl), or epoxy groups.
- the particles of the present disclosure are not made entirely from unfunctionalized poly(lactic-co-glycolic acid) (PLGA), which historically can be difficult to functionalize.
- PLGA poly(lactic-co-glycolic acid)
- unfunctionalized PLGA could be incorporated into portions of a copolymer backbone that also includes other functionalized polymers in the copolymer backbone.
- Functionalization of the polymers of the present disclosure can enable one of skill in the art to customize the features of the particles.
- the adjustment of the ratios and types of crosslinker and polymer can allow for alterations in, e.g., porosity, drug loading and release, and rates of degradation.
- polyester backbones can be used to form particles of the present disclosure.
- the polyester backbones are made from polycaprolactone (PCL).
- the polyester backbones are made from polyvalerolactone (PVL).
- the PCL or PVL can be functionalized with an allyl group to produce polyallylcaprolactone (PACL) or polyallylvalerolactone (PAVL).
- polyesters of the present disclosure are copolymers comprising two or more different monomers.
- polyesters can comprise PVL and PAVL; PCL and PACL; PVL and PACL; or PCL and PAVL.
- polyesters of the present disclosure can further comprise polylactic acid and/or polyglycolic acid.
- any of the polyvalerolactone, polycaprolactone, polylactic acid, or polyglycolic acid can be functionalized with a functional group.
- any of the polyvalerolactone, polycaprolactone, polylactic acid, or polyglycolic acid can further include an ally group, a propargyl group, or a carboxylic acid (or carboxylic acid derivative) disposed along the polymer backbone.
- the functional group can be used to crosslink the polymer backbone with another polymer backbone.
- the copolymers of the disclosure can be block copolymers or random copolymers.
- the polyester backbone can comprise a copolymer of polyvalerolactone and polyallylvalerolactone (PVL-co-PAVL):
- n and n are integers and can each independently fall between about 1 and 1,000. For instance, when n is about 48 and m is about 15, the molecular weight is about 7,000 g/mol. When n is about 128 and m is about 14, the molecular weight is about 14,760 g/mol.
- the polyester backbone can comprise a stabilizer (e.g., a PEG stabilizer).
- a polyester backbone can comprise mPEG2k-b-PVL-co-PAVL:
- m, n and q are each integers and can each independently fall between about 1 and 1,000.
- q is about 50
- n is about 40
- m is about 9
- the molecular weight of the polyester is about 7,500 g/mol.
- the polyester backbone can comprise polyallyl lactide.
- the polyallyl lactide can be formed from polymerization of allyl lactide.
- a polyester backbone can comprise a copolymer of polyvalerolactone and polyallyllactide (PVL-co-PAL):
- the polyesters of the present disclosure can be prepared using a variety of different suitable monomers.
- valerolactone can be used to prepare polyvalerolactone
- allylvalerolactone can be used to prepare polyallylvalerolactone.
- caprolactone can be used to prepare polycaprolactone
- allylcaprolactone can be used to prepare polyallylcaprolactone.
- lactic acid, glycolic acid, allyl lactide, and combinations thereof can be used as monomers to prepare the polyesters disclosed herein.
- One of skill in the art will readily understand how to select an appropriate monomer to arrive at a desired polyester backbone.
- the polyesters of the present disclosure can further comprise polyethyleneglycol (PEG).
- PEG polyethyleneglycol
- the PEG can connect two different sections of polyester. That is, the PEG can be dispersed between ester-containing portions of the polyester backbone.
- the PEG can be attached at the end of the polymer (i.e., the PEG can comprise a terminal portion of the polymer).
- the PEG is found primarily towards the outside of the microparticles.
- crosslinked polymers of the present disclosure can further include additional polymers entangled therein.
- compositions of the present disclosure can include PVL and/or PAVL polymer backbones crosslinked together.
- the present disclosure includes PVL and/or PAVL polymer backbones crosslinked together with PCL entangled therein.
- the present disclosure can include PVL and/or PAVL polymerized onto PCL backbones, or PVL and or PAVL portions crosslinked together.
- the present disclosure can include PVL and/or PAVL and PEG polymer backbones crosslinked together.
- crosslinking can take place in the presence of a radical initiator (e.g., a photoinitiator).
- the crosslinking reaction can be a radical thiol-ene reaction.
- a photoinitiator i.e., 2,2-dimethoxy-2-phenylacetophenone
- a photoinitiator can be used to crosslink a hexanedithiol crosslinker with the allyl functional groups present on a PAVL-PVL polymer backbone.
- a photoinitiator can be used create radicals (e.g., in the presence of UV light). In some embodiments, photoinitiators do not require heat to produce radicals.
- the radicals thus created can initiate a thiol-ene chain reaction between the thiols on the hexanedithiol with the olefin functionality (e.g., of the ally group) of PAVL to crosslink the polyester backbones and produce particles (e.g., microparticles or nanoparticles).
- additional radical initiators can be used to initiate a crosslinking reaction such as the thiol-ene reaction.
- radical initiators can include, without limitation, thermal initiators, halogens such as chlorine, bromine, and iodine, azo compounds such as azobisisobutyronitrile (AIBN), and organic peroxides such as di-tert-butyl peroxide and benzoyl peroxide.
- thermal initiators halogens such as chlorine, bromine, and iodine
- azo compounds such as azobisisobutyronitrile (AIBN)
- organic peroxides such as di-tert-butyl peroxide and benzoyl peroxide.
- the radical initiator can be a drug itself.
- a drug can be an initiator for crosslinking of the polymer backbones (e.g., polyester backbone) to form a particle of the present disclosure.
- the radical initiators of the present disclosure need not be photoinitiators.
- the radical initiators used herein can create radicals, for instance, thermally (e.g., upon heating).
- the amount of time necessary to crosslink polyesters using UV exposure can be, for instance, between about 1 and about 60 minutes.
- an emulsion of the present disclosure can be exposed to UV light for about 1, about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, or about 60 minutes.
- crosslinking can take place via the formation of a triazole from the reaction between an alkyne group and an azide group.
- polyesters of the present disclosure can be functionalized with an alkynyl group (e.g., a propargyl group).
- the alkynyl group can react in the presence of a diazide (e.g., 1,6-hexanediazide).
- the alkynyl groups on the polyester chains can react to form triazoles with the crosslinkers (e.g., via the azide-alkyne Huisgen cycloaddition), thus creating particles (e.g., microparticles).
- this reaction can be carried out in the presence of a catalyst.
- the cycloaddition reaction can be carried out in the presence of a copper (I) salt (e.g., cuprous bromide or cuprous iodide).
- a copper (II) salt e.g., copper (II) sulfate
- a reducing agent e.g. sodium ascorbate
- the cycloaddition reaction takes place in the absence of a catalyst.
- the cycloaddition reaction can take place upon heating the mixture.
- crosslinking can take place via the formation of amide bonds (—C(O)NR—).
- crosslinking can be effected by amide formation between a polyester of the disclosure that has been functionalized with a carboxylic acid group (or a carboxylic acid derivative) and a diamine (e.g., 1,6 hexanediamine).
- the amide formation can take place in the presence of a peptide coupling catalyst such as N,N′-Dicyclohexylcarbodiimide (“DCC”), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (“HBTU”), or 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (“HATU”).
- DCC N,N′-Dicyclohexylcarbodiimide
- HBTU 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
- HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate
- amide bonds can be formed by heating a mixture of carboxylic acid groups (e.g., in the presence of an acid).
- amide bonds can be formed between amines and carboxylic acid derivatives.
- a crosslinking amide bond can be formed by treatment of an ester or non-crosslinked amide with a crosslinking amine group.
- crosslinking can take place via the formation of a ⁇ -hydroxy amine.
- crosslinking can take place between an epoxide group disposed along a polyester backbone as described herein and an amine moiety.
- the diamines can react with the epoxides (e.g., nucleophilic attack) to form carbon-nitrogen bonds.
- the regiochemistry of the O-hydroxy amine-forming reaction can be controlled by the reaction conditions (e.g., use of acid or basic catalysis). For example, one can influence whether a monosubstituted epoxide opens at the terminal position by using basic catalysis.
- the nucleophile can be a molecule wherein the nucleophilic site has an atom with an additional lone pair of atoms alpha to the nucleophilic atom (e.g., can be an “alpha effect” nucleophile).
- the nucleophilic portion of the crosslinker can be a hydrazine, a peroxide, or a hydroxylamine.
- particles (e.g., microparticles) of the present disclosure can be crosslinked by a reaction between a tetrazine and a trans-cyclooctene.
- crosslinking can take place as set forth in Scheme 5, below.
- One of skill in the art will understand that a variety of different regiochemistries is possible with a tetrazine-trans-cyclooctene reaction.
- treatment of a trans-cyclooctene functionalized backbone (13) can be crosslinked with a ditetrazine (14).
- the tetrazine group can react with the trans-olefin of the cyclooctene group (e.g., a Diels-Alder cycloaddition followed by elimination of nitrogen gas).
- the regiochemistry of tetrazine addition can vary.
- the flexibility in regiochemical crosslinking is also shown in Formula V.
- Formula V shows that the crosslinking reaction is not limited to a specific regiochemistry (e.g., the trans-cyclooctene can be attached to the polymer backbone at different positions than the position shown).
- particles (e.g., microparticles) of the present disclosure can be crosslinked by a reaction between a thiol and a norbornene.
- crosslinking can take place as set forth in Scheme 6, below.
- One of skill in the art will understand that a variety of different regiochemistries is possible with a thiol-norbornene reaction, and the present disclosure is not limited to a specific regiochemistry.
- treatment of a norbornane-functionalized backbone (16) can be crosslinked with a dithiol (17) in the presence of ultraviolet light to form a crosslinked particle (18).
- a photoinitiator can be added.
- the thiol group can react with the olefin of the norbornyl group to form sulfur-carbon bonds (e.g., by radical addition).
- the regiochemistry of thiol addition can vary.
- the flexibility in regiochemical crosslinking is also shown in Formula VI.
- Formula VI shows that the norbornyl group can be connected to the polymer backbone and crosslinked via a dithiol with a variety of different crosslinking regiochemistries, and the present disclosure is not limited to a specific regiochemistry.
- crosslinkers can have two functional groups (i.e., the crosslinkers can be linear and have a functional group at each end). Examples of such bifunctional crosslinkers are 1,6-hexanedithiol.
- crosslinkers can be multifunctional (e.g., can have more than two functional groups).
- a tetrafunctional crosslinker can have the structure of 4,4-bis(3-aminopropyl)heptane-1,7-diamine:
- tetrafunctional crosslinker can be used, for instance, in the presence of epoxy-functionalized polymer backbones. Additionally, one of skill in the art will understand that the amine functionalities can be replaced with thiol groups to enable a tetrafunctional crosslinker in a thiol-ene reaction.
- crosslinkers of the present disclosure can comprise polymer (e.g., polyester, polycarbonate backbones).
- the crosslinker can comprise a polymer with functional groups disposed thereon that are capable of reacting with the functional groups of another polymer.
- a polyester backbone comprising a plurality of allyl groups disposed thereon can be crosslinked by a polyester polymer comprising a plurality of free thiol groups disposed thereon.
- the crosslinking polymer can comprise a plurality of monomer units (e.g., 100 or more, 200 or more, 300 or more, or 1000 or more monomer units).
- the monomer units can be functionalized or unfunctionalized valerolactone units.
- the particles can be microparticles or nanoparticles.
- the particles described herein can have diameters between about 1 and 999 ⁇ m, including all ranges and subranges therebetween (e.g., between about 5 and about 500 ⁇ m; or about 10 ⁇ m; about 20 ⁇ m; about 50 ⁇ m; about 100 ⁇ m; or about 200 ⁇ m).
- Size optimization or size control can be accomplished by a number of different methods described herein.
- the polymers and crosslinkers described herein can be dissolved in a non-aqueous (e.g., organic) solvent.
- the mixture of the polymers and crosslinkers (and, optionally, initiators or catalysts) can be emulsified with an aqueous phase (e.g., water optionally comprising an emulsifying agent such as polyvinylalcohol, PVA, or PEG).
- an emulsifying agent such as polyvinylalcohol, PVA, or PEG.
- the particle precursors e.g., polymers, crosslinking agents and initiators
- the particle precursors can be dissolved within droplets of the non-aqueous solvent of the emulsion.
- the crosslinking reaction can then take place while the particle precursors are dissolved in the non-aqueous solvent of the emulsion.
- the emulsion i.e., the non-aqueous phase
- the crosslinking can take place within the emulsion (i.e., the non-aqueous phase).
- an emulsion comprising non-aqueous droplets with the particular precursors (e.g., polyester backbone and crosslinker) dissolved therein can be irradiated.
- the particular precursors e.g., polyester backbone and crosslinker
- all of the components of the reaction are water-insoluble and therefore dissolve in the non-aqueous droplets of the emulsion.
- the size of the microparticles is a function of the size of the droplets (e.g., microdroplets) of the non-aqueous solvent.
- the speed of stirring or agitation of the emulsion can be used to control the size of the non-aqueous droplets and thus the size of the resulting microparticles.
- sonication e.g., by probe tip or horn
- polymer precursors e.g., PCL
- the speed of the emulsion process can be adjusted between about 10,000 rpm and 22,000 rpm.
- the speed of the emulsion process can be about 10,000 rpm, about 11,000 rpm, about 12,000 rpm, about 13,000 rpm, about 14,000 rpm, about 15,000 rpm, about 16,000 rpm, about 17,000 rpm, about 18,000 rpm, about 19,000 rpm, about 20,000 rpm, about 21,000 rpm, or about 22,000 rpm.
- the percentage of surfactant (e.g., polyvinyl alcohol, polyvinylpyrollidone or polyethylene glycol) in the aqueous phase can also be used to control the droplet size (and thus the size of the resulting particles).
- the viscosity of the aqueous phase can be controlled by the amount of polyvinyl alcohol.
- the percentage of polyvinyl alcohol can be between about 5% (wt) and about 20% (wt).
- the percentage of polyvinyl alcohol can be about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% by weight.
- the molecular weight of the surfactant e.g., polyvinyl alcohol, polyvinylpyrollidone or polyethylene glycol
- the molecular weight of the surfactant can be used to control the droplet size (and thus the size of the resulting particles).
- the ratio of aqueous solvent to non-aqueous solvent can also be used to control the size of the particles. For example, in some embodiments, between about 1 and 100 mL of aqueous solvent is used (e.g., about 1, about 5, about 10, or about 15 mL of aqueous solvent). In some embodiments, between about 1 and about 10 mL of non-aqueous solvent is used (e.g., about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9 or about 10 mL of non-aqueous solvent is used). In some embodiments, the ratio of aqueous to non-aqueous solvent is between about 1:1 to about 10:1.
- the solvent e.g., the non-aqueous solvent, the aqueous solvent, or both
- removal of the solvent includes exposing the emulsion to a gas stream (e.g., an N2 stream).
- the gas stream can last for a number of hours (e.g., about 1 hour, about 3 hours, about 6 hours, about 12 hours, or about 24 hours).
- the microparticles and macroparticles of the present disclosure can be controlled by photolithography.
- templates were formed by creating pegs of uniform size and shape which were used to create wells that are likewise of uniform size and shape.
- Polyesters and crosslinkers were dissolved in the wells and crosslinked to created microparticles and macroparticles of uniform size.
- the resulting particles can then be removed from the wells and used.
- the molded solution can also contain a filler (e.g., a plasticizer).
- the filler can be used to control the porosity of the resulting particles.
- the size of the particles can be controlled by milling of a corresponding macroparticle.
- the crosslinking reactions of the present disclosure can be performed in a single phase (i.e., not an emulsion) to create a macroscopic particle (e.g, a particle with a mass of >10 mg).
- the resulting macroparticle can then be milled (e.g., crushed) to create a plurality of nanoparticles or microparticles.
- particles of the present disclosure can comprise PEG polymers attached to the polyester particle backbone.
- the PEG polymers can be attached such that they are disposed toward the outside of the particle.
- the PEG polymers can be attached at the terminal portion of the polyester particle backbones.
- attachment of PEG polymers can help to reduce aggregation of the particles of the present disclosure.
- other polymers such as polyvinylpyrrolidone or pluronics can be used in place of PEG to help prevent aggregation.
- attachment of PEG polymers can make the particles more hydrophilic and help facilitate drug loading.
- a PVL-co-PAVL microparticle was prepared according to the methods disclosed herein. Without wishing to be bound by theory, the resulting particles were hydrophobic and demonstrated some aggregation. In some embodiments, it could be difficult to load drugs into the resulting particles because the particles were non-porous and hydrophobic.
- attachment of PEG polymers can be accomplished by using a hydroxy-PEG molecule as an initiator for a polymerization reaction (e.g., as an initiator for polyester formation).
- a hydroxy-PEG molecule as an initiator for a polymerization reaction
- a multi-arm PEG such as a PEG dendrimer or a six-arm, hydroxy terminated PEG can be used as a polymerization initiator.
- preparation of particles comprising mPEG-2K-PVL-co-PAVL i.e., particles wherein PEG was disposed on the outside of the particle
- at least about 2.5% PEG can be used (e.g., as a co-solvent) to reduce aggregation of drug particles (e.g., at least about 2.5%, at least about 5%, or at least about 10%).
- FIG. 18 A shows curcumin-loaded particles dissolved in water containing 1% tween after being dried in THF with 25% PEG as a co-solvent.
- FIG. 18 A shows curcumin-loaded particles dissolved in water containing 1% tween after being dried in THF with 25% PEG as a co-solvent.
- drugs can be loaded into the particles of the present disclosure by soaking the particles in a solvent (e.g., water, tetrahydrofuran (THF) or dimethylsulfoxide (DMSO)) that contains the drug.
- a solvent e.g., water, tetrahydrofuran (THF) or dimethylsulfoxide (DMSO)
- the drug can be a small molecule, including, but not limited to, triamcinolone, triamcinolone hexacetonide, paclitaxel.
- drugs include, but are not limited to, bimatoprost, travaprost, brimonidine, camptothecin, tamoxifen, quercetin, thiostrepton, temozolamide, trametinib, seliciclib, fN′LFN′ YK, GCGGGDHGVSSGV, hepatocyte growth factor (HGF), and bone morphogenetic protein 2 (BMP2).
- the drugs released from particles of the present disclosure can be hydrophobic.
- particle loading with such hydrophobic drugs and subsequent release from the particles can facilitate the administration of such hydrophobic drugs (e.g., in vivo).
- FIG. 13 gives loading capacities of macroparticles of the present disclosure for the drugs curcumin (as a visible surrogate for a drug), paclitaxel, triamcinolone acetonide, and triamcinolone hexacetonide.
- the particles e.g., microparticles such as 10 ⁇ m microparticles
- can provide sustained release e.g., about 3 months of sustained release of a drug (e.g., triamcinolone hexacetonide) in a relevant animal model.
- a drug e.g., triamcinolone hexacetonide
- FIG. 4 shows a schematic of the method for loading drugs into particles of the present disclosure.
- particles are suspended in an organic solvent containing a drug.
- the resulting mixture is stirred, and the drug can incorporate into the porous regions of the particles.
- the drugs can be lyophilized and stored until use.
- the loading procedure can affect the amount of drug that is absorbed into a particle of the present disclosure.
- 25 mg of 75:25 (mPEG-PVL-PAVL:PVL-PAVL) particles were swollen overnight with 2 mg/mL triamcinolone hexacetonide in THF.
- slow addition of greater volumes of water can facilitate greater uptake of triamcinolone hexacetonide by allowing the drug to preferentially partition into the particles.
- slow addition of water enabled 67% loading efficiency.
- Additional parameters, in addition to the rate of water addition, that can affect the loading of a drug into a particle of the present disclosure are, for instance, the solvent in which the drug is dissolved, the time that the particles soak with the drug, and the volume of water used.
- Other parameters include the pH and the ionic strength of the solvent.
- protic organic solvents such as methanol or ethanol can be used in place of water to facilitate loading of drug into a particle of the present disclosure.
- Example 5 shows that particles of the present disclosure can change in size (e.g., can swell) depending on the solvent in which they are placed.
- FIG. 5 shows a histogram of crosslinked mPEG-b-(PVL-coPAVL) microparticles demonstrating that had an average diameter of about 79 nm when placed in water.
- the same particles swelled to a diameter of about 85 nm when soaked in dimethylsulfoxide (DMSO) as set forth in FIG. 6 .
- DMSO dimethylsulfoxide
- a particle soaked in THF can be about 2 ⁇ as large, about 3 ⁇ as large, about 4 ⁇ as large, about 5 ⁇ as large, about 6 ⁇ as large, about 7 ⁇ as large, about 8 ⁇ as large, about 9 ⁇ as large, about 10 ⁇ as large, about 11 ⁇ as large, about 12 ⁇ as large, about 13 ⁇ as large, about 14 ⁇ as large, about 15 ⁇ as large, about 16 ⁇ as large, about 17 ⁇ as large, about 18 ⁇ as large, about 19 ⁇ as large, or about 20 ⁇ as large, as a particle soaked in water.
- FIG. 8 sets forth a histogram of non-crosslinked mPEG-b-PVL-co-PAVL microparticles after soaking in water.
- FIG. 9 sets forth the swelling of particles that have been suspended in THF.
- FIG. 9 A shows a histogram and an image of microparticles after crosslinking.
- FIG. 9 B and FIG. 9 C show histograms and images of microparticles after a DMSO washing step and an ethanol washing step, respectively.
- FIG. 9 D shows images and a histogram of particles soaked in THF. As set forth in FIG. 9 D , the THF-soaked particles can be larger than the particles soaked in other solvents such as water or ethanol.
- the release of drugs from particles of the present disclosure can be dependent upon the crosslinking density of the particles.
- high crosslinking density can lead to slower drug release as high crosslinking density can lead to slower hydrolysis and thus slower degradation of the particles.
- the release of drugs from particles of the present disclosure can be dependent upon the density of the particles. For instance, in some embodiments increasing the length of the crosslinker can decrease the density of the particle and allow for faster release of drug from a given particle.
- the particles disclosed herein display low crystallinity.
- the low crystallinity can be advantageous for diffusion-mediated release.
- FIGS. 28 and 29 shows that microparticles of the present disclosure have low crystallinity at high crosslinking density.
- FIG. 10 shows a 1 HNMR spectrum of PVL-co-PAVL polymer with a molecular weight of 17200 g/mol (i.e., about 128 units of valerolactone and about 14 units of allylvalerolactone).
- the number average molecular weight of the polymer was about 12,200 g/mol, with a peak molecular weight of about 14100 g/mol.
- the polydispersity index was bout 1.41.
- the melting temperature was about 35° C.
- the temperature of recovery was about 11° C.
- FIG. 10 B shows a gel permeation chromatography plot of the PVL-co-PAVL nanoparticles.
- the mixture was subjected to gel permeation chromatography.
- the weight average molecular weight was about 17,200 g/mol.
- Allyl lactide is prepared according the method disclosed in U.S. Pat. No. 8,758,828 to Markland, et. al. Benzyl alcohol, valerolactone and allyl lactide are dissolved in triazabicyclodecene and stirred at room temperature for 4 hours. The resulting polymer is isolated and used for crosslinking microparticles.
- Polycaprolactone homopolymer (PCL; 50 mg; 50 kDa; 1 mmol), polyvalerolactone (PVL; 50 mg) and polyallylvalerolactone (PAVL; 50 mg (6700 g/mol; 19% allylvalerolactone and 81% valerolactone)) and hexanedithiol (1 —SH group per alkene) were dissolved in 1 mL dichloromethane.
- 2,2-Dimethoxy-2-phenylacetophenone (DMPA; 3.4 mg; 0.2 equivalents per alkene) was added and the solution was added dropwise to 20 mL of water containing 5% polyvinyl alcohol.
- the mixture was homogenized with stirring (i.e., a Polytron® mechanical homogenizer at 22,000 rpm) for five minutes.
- the homogenized mixture was irradiated at 365 nm-4 mW under stirring for 30 minutes.
- the mixture was stirred for 3 hours to allow the dichloromethane to evaporate.
- the mixture was then centrifuged at 4000 rpm at 10° C. for 10 minutes.
- the aqueous solution containing polyvinyl alcohol was poured off and the particles were rinsed with distilled water.
- the particles were then centrifuged and rinsed with water as above an additional three times.
- the particles were then dispersed in DMSO and centrifuged at 4000 rpm at 20° C. for ten minutes. The DMSO was poured off and the process was repeated another two times. The resulting crosslinked particles were swollen and semi-transparent and did not dissolve in DMSO.
- FIG. 1 A shows a photo of a PCL-co-PAVL copolymer at a scale of about 1500 ⁇ m produced by the above-method.
- FIGS. 1 B, 1 C, and 1 D show photos of a PCL-co-PAVL/PVL copolymer produced by the above-method at a scale of 400 ⁇ m, 600 ⁇ m, and 20 ⁇ m, respectively.
- the particles comprised between 0.01% and 20% polyallylvalerolactone (PAVL), with the remainder comprising polycaprolactone (PCL) and polyvalerolactone (PVL).
- Polycaprolactone homopolymer (PCL; 50 mg; 50 kDa; 1 mmol) and polyallylvalerolactone (PVL-co-PAVL; 50 mg) were dissolved in 1 mL dichloromethane. The solution was added dropwise to 20 mL of water containing 5% polyvinyl alcohol. The mixture was homogenized with stirring (i.e., a Polytron® mechanical homogenizer at 22,000 rpm) for five minutes. The homogenized mixture was irradiated at 365 nm-4 mW under stirring for 30 minutes. No crosslinker or DMPA was added.
- PCL Polycaprolactone homopolymer
- PVL-co-PAVL polyallylvalerolactone
- the mixture was stirred for 3 hours to allow the dichloromethane to evaporate.
- the mixture was then centrifuged at 4000 rpm at 10° C. for 10 minutes.
- the aqueous solution containing polyvinyl alcohol was poured off and the particles were rinsed with distilled water.
- the particles were then centrifuged and rinsed with water as above an additional three times.
- Polyallylvalerolactone (PAVL; 100 mg (6700 g/mol; 19% allylvalerolactone and 81% valerolactone)) and hexanedithiol (1 —SH group per alkene) were dissolved in 1 mL dichloromethane. 2,2-Dimethoxy-2-phenylacetophenone (DMPA; 0.2 equivalents per alkene) was added and the solution was added dropwise to 20 mL of water containing 5% polyvinyl alcohol. The mixture was homogenized with stirring (i.e., a Polytron® mechanical homogenizer at 22,000 rpm) for five minutes. The homogenized mixture was irradiated at 365 nm-4 mW under stirring for 30 minutes.
- stirring i.e., a Polytron® mechanical homogenizer at 22,000 rpm
- the mixture was stirred for 3 hours to allow the dichloromethane to evaporate.
- the mixture was then centrifuged at 4000 rpm at 10° C. for 10 minutes.
- the aqueous solution containing polyvinyl alcohol was poured off and the particles were rinsed with distilled water.
- the particles were then centrifuged and rinsed with water as above an additional three times.
- the particles were then dispersed in DMSO and centrifuged at 4000 rpm at 20° C. for ten minutes. The DMSO was poured off and the process was repeated another two times. The resulting crosslinked particles were swollen and semi-transparent and did not dissolve in DMSO.
- FIG. 2 A shows a photo of a PVL-co-PAVL copolymer at a scale of about 1500 ⁇ m produced by the above-method.
- FIGS. 2 B, 2 C, and 2 D show photos of a PVL-co-PAVL copolymer produced by the above-method at a scale of 400 ⁇ m, 600 ⁇ m, and 20 ⁇ m, respectively.
- Polyallylvalerolactone (PAVL; 100 mg) was dissolved in 1 mL dichloromethane. The solution was added dropwise to 20 mL of water containing 5% polyvinyl alcohol. The mixture was homogenized with stirring (i.e., a Polytron® mechanical homogenizer at 22,000 rpm) for five minutes. No DMPA or crosslinker was added. The homogenized mixture was irradiated at 365 nm-4 mW under stirring for 30 minutes.
- stirring i.e., a Polytron® mechanical homogenizer at 22,000 rpm
- the mixture was stirred for 3 hours to allow the dichloromethane to evaporate.
- the mixture was then centrifuged at 4000 rpm at 10° C. for 10 minutes.
- the aqueous solution containing polyvinyl alcohol was poured off and the particles were rinsed with distilled water.
- the particles were then centrifuged and rinsed with water as above an additional three times.
- FIG. 5 shows a DLS plot of the crosslinked particles in water. As shown, the particles are about 100 nm in diameter. Table 2 below shows the results of the DLS analysis.
- FIG. 6 shows a DLS plot of the crosslinked particles in DMSO. As shown, the particles are about 100 nm in diameter. Table 3 below shows the results of the DLS analysis.
- FIG. 7 shows a DLS plot of the crosslinked particles in THF. As shown, the particles are between about 100 nm and 1000 nm in diameter. Table 4 below shows the results of the DLS analysis.
- FIG. 11 A shows a microscope image of mPEG-b-PAVL-co-PVL macroparticles (80:20) produced by this method at a resolution of about 1 mm.
- FIG. 11 B shows a microscope image of mPEG-b-PAVL-co-PVL macroparticles (80:20) produced by this method at a resolution of about 200 ⁇ m.
- FIG. 11 C shows a first microscope image of mPEG-b-PAVL-co-PVL macroparticles (80:20) produced by this method at a resolution of about 10 ⁇ m.
- FIG. 11 D shows a second microscope image of mPEG-b-PAVL-co-PVL macroparticles (80:20) produced by this method at a resolution of about 10 ⁇ m.
- FIG. 8 shows a DLS image of non-crosslinked microparticles produced as in the method above in water
- FIG. 12 shows a DLS plot of non-crosslinked particles in water. As shown, the particles are about 100 nm in diameter. Table 5 below shows the results of the DLS analysis. Without wishing to be bound by theory, because the particles were not crosslinked, they re-dissolved in organic solvent.
- the particles did not easily resuspended in 10 mL water containing 0.1% tween. Without wishing to be bound by theory, this may be due to the fact that the triamcinolone hexacetonide crystallized on the surface of the particles. Without wishing to be bound by theory, this may be due to the relatively fast addition of water and the limited solubility of triamcinolone hexacetonide, which caused it to crystallize. Also without wishing to be bound by theory, the release profile showed relatively rapid release from the particles, likely a result of the surface-crystallized drug re-dissolving in solution.
- microparticles were swollen in 0.5 mL of tetrahydrofuran containing 10 mg of drug. Slow addition of water was used in some embodiments for the addition to microparticles.
- the loading efficiency which included surface-bound drug or free drug in solution, was 67%.
- 20% of the triamcinolone hexacetonide was released within an hour, and 30% was released within 2 hours.
- FIG. 13 shows the loading capacity of the 15-mg macroparticles of the present disclosure with curcumin (CCM), triamcinolone hexacetonide (TAH), triamcinolone acetonide (TAA), and paclitaxel (PTX).
- CCM curcumin
- TH triamcinolone hexacetonide
- TAA triamcinolone acetonide
- PTX paclitaxel
- FIG. 14 shows differential scanning calorimetry plots of macroparticles loaded with curcumin (CCM), triamcinolone hexacetonide (TAH), triamcinolone acetonide (TAA), and paclitaxel (PTX) and without drugs.
- FIG. 15 shows FTIR spectra of microparticles loaded with curcumin (CCM), triamcinolone hexacetonide (TAH), triamcinolone acetonide (TAA), and paclitaxel (PTX) and without drugs.
- Crosslinked microparticles (15 mg) were loaded with 2.5 mg curcumin by overnight soaking in THF followed by the slow addition of 50 mL PBS containing 0.1% Tween. The microparticles were rinsed with THF to remove free curcumin and dried overnight.
- microparticles thus produced formed “flakes” that could not be re-suspended in THF or PBS buffer solution upon drying.
- Microscope images of the flakes are shown in FIG. 16 after being dried overnight, and FIG. 17 shows a release profile of curcumin from microscopic flakes. The flakes could not be re-suspended in PBS buffer.
- FIGS. 18 A and 18 B show microscope images of microparticles of the invention after being dried with 25% PEG 400 as a co-solvent.
- FIG. 19 A shows a microscope image of microparticle flakes in water after drying with 2.5% PEG 400 as a co-solvent.
- FIG. 19 B shows a microscope image of microparticle flakes in THF after drying with 2.5% PEG 400 as a co-solvent.
- FIG. 19 C shows a microscope image of microparticle flakes in water after drying with 5% PEG 400 as a co-solvent.
- FIG. 19 D shows a microscope image of microparticle flakes in THF after drying with 5% PEG 400 as a co-solvent.
- FIGS. 18 and 19 demonstrate that as little as 2.5% PEG 400 was capable of re-suspending microparticle flakes.
- FIG. 9 A shows a histogram and a optical microscope image of 25% PVL-co-PAVL microparticles after crosslinking. The average diameter was 6.8 ⁇ m ⁇ 2.5 nm.
- FIG. 9 B shows a histogram and OM image of the same microparticles after a DMSO washing step (average diameter 6.4 ⁇ m ⁇ 1.8 nm) and
- FIG. 9 C shows a histogram and OM image of the particles after an ethanol washing step (average diameter 8 ⁇ m ⁇ 2.5 nm).
- FIG. 9 D shows a histogram and OM image of the particles after swelling in THF, after which the average diameter was 11.1 ⁇ m ⁇ 4.5 nm. The results show that in some embodiments, suspending the particles in THF causes the particles to swell.
- Triamcinolone acetonide, triamcinolone hexacetonide, and paclitaxel were dissolved in water with varying concentrations of surfactants as co-solvents.
- Sodium dodecyl sulfate (SDS) is an anionic surfactant with a critical micelle concentration (CDC) of 8.2 mM.
- the hydrophobic lipophilic balance (HLB) is 40.
- Tween 80 is a non-ionic surfactant with a critical micelle concentration (CMC) of 0.012 mM, and a hydrophobic lipophilic balance (HLB) of 15.
- FIG. 20 shows that certain drugs can by hydrophobic, and can require addition of surfactants (e.g. sodium dodecyl sulfate and Tween 80) to dissolve in water.
- FIG. 20 A shows an aqueous solubility plot of triamcinolone acetonide in the presence of surfactants Tween 80 and SDS.
- FIG. 20 B shows an aqueous solubility plot of triamcinolone hexacetonide in the presence of surfactants Tween 80 and SDS.
- FIG. 20 C shows an aqueous solubility plot of paclitaxel in the presence of surfactants Tween 80 and SDS.
- the macroparticles were suspended in PBS (0.1% Tween) and the release rate was observed.
- the macroparticles released 5% of the paclitaxel after 3 hours at room temperature and about 5% after 24 hours at room temperature.
- the loading capacity was found to be 1.7% w/w, and the loading efficiency was 30%.
- FIG. 21 shows that almost all of the curcumin is released after about eight days.
- mechanical agitation e.g., stirring with a stir bar
- FIG. 22 shows a 20-day curcumin release profile from a 13-mg and 12-mg macroparticle.
- FIG. 23 shows that the release profile for both cylinders is very similar, and that about 60% of total drug is released after about 6 days.
- FIG. 24 shows a 20-day triamcinolone hexacetonide release profile from a 13.3-mg and 9.2-mg macroparticle.
- FIG. 25 shows a comparison of the release profiles of curcumin, triamcinolone hexacetonide (TAH), triamcinolone acetonide (TAA), and paclitaxel (PTX).
- TH triamcinolone hexacetonide
- TAA triamcinolone acetonide
- PTX paclitaxel
- Microparticles were fabricated with a silicon master template with 10 ⁇ m cylindrical pegs which serve as the inverse for a degradable gelatin template (i.e., the pegs can control the size of the wells.
- Wells on a gelatin template were filled with polymer solution, crosslinked, and harvested. The resulting particles had a homogenous size distribution.
- FIG. 26 shows an example micrograph of the photolithography template (G. Acharyo; Journal of Controlled Release 141; 2010; pp. 314-319).
- FIG. 27 A shows a gelatin template with pegs under a microscope.
- FIGS. 27 B and 27 C show microscope images of microparticles prepared by the above-method.
- FIG. 28 shows DSC plots of microparticles with different degrees of crosslinking. The DSC plots measured the enthalpy of melting ( ⁇ °H m ) of particles freeze dried for four days.
- FIG. 28 A shows a DSC plot of a control microparticle with no crosslinking and shows relatively high crystallinity.
- FIG. 28 B shows a DSC plot of a microparticle with 50% crosslinking. The DSC plot shows relatively low crystallinity.
- FIG. 28 C shows a DSC plot of a microparticle with 100% crosslinking. The DSC plot shows even lower crystallinity than the 50% crosslinked particles.
- FIG. 29 shows DSC plots of microparticles with different degrees of crosslinking.
- the DSC plots measured the enthalpy of melting ( ⁇ °H m ) of particles freeze dried for four days.
- FIG. 29 A shows a DSC plot of a control microparticle with no crosslinking (i.e., just the polymer backbone is analyzed).
- FIG. 29 B shows a DSC plot of a microparticle with 50% crosslinking. The DSC plot shows low crystallinity.
- FIG. 29 C shows a DSC plot with 100% crosslinking. The DSC plot shows low crystallinity. Without wishing to be bound by theory, the low crystallinity of the drug can help facilitate diffusion-mediated release.
- the middle trace shows a trace of 10% PAVL microparticles.
- the number average molecular weight (Mn) was 12,000 and the weight average molecular weight (Mw) was 17,500.
- the polydispersity index (PDI) was 1.45.
- the particles were found to be semi-crystalline and the melting temperature was found to be between about 25-35° C.
- the top trace shows a trace of 8% PAVL microparticles.
- the number average molecular weight (Mn) was 32,700 and the weight average molecular weight (Mw) was 50,000.
- the polydispersity index (PDI) was 1.55. The particles were found to be an amorphous rubber.
- mice were implanted in hind limb with GL261 glioma cells and were treated with fluorescently labeled GIRLRG peptide and daily radiation of 3 Gy for 3 days. Mice were similarly treated with systemic taxol, taxol-loaded, control peptide particles, taxol-loaded targeted microparticles, and naked particles.
- Polyvalerolactone (PVL; 50 mg) and poly(trans-cyclooctene)valerolactone (PtCOVL; 50 mg (6700 g/mol; 19% (trans-cyclooctene)valerolactone and 81% valerolactone)) and hexanedi-tetrazine (1 tetrazine group per trans-cyclooctene) are dissolved in 1 mL dichloromethane.
- the solution is added dropwise to 20 mL of water containing 5% polyvinyl alcohol.
- the mixture is homogenized with stirring (i.e., a Polytron® mechanical homogenizer at 22,000 rpm) for five minutes.
- the homogenized mixture is stirred for about an additional 12-48 hours.
- the mixture is then centrifuged at 4000 rpm at 10° C. for 10 minutes.
- the aqueous solution containing polyvinyl alcohol is poured off and the particles are rinsed with distilled water.
- the particles are then centrifuged and rinsed with water as above an additional three times.
- Polyallylvalerolactone (PAVL; 100 mg (6700 g/mol; 19% allylvalerolactone and 81% valerolactone)) and hexanedithiol (1 —SH group per alkene) are dissolved in 1 mL dichloromethane.
- 2,2-Dimethoxy-2-phenylacetophenone (DMPA; 0.2 equivalents per alkene) is added and the solution is sprayed on to a 20 mL water bath containing 5% polyvinyl alcohol using an electrosprayer. The electrosprayed droplets and the homogenized mixture are irradiated at 365 nm-4 mW under stirring for 30 minutes.
- the mixture is stirred for 3 hours to allow the dichloromethane to evaporate.
- the mixture is then centrifuged at 4000 rpm at 10° C. for 10 minutes.
- the aqueous solution containing polyvinyl alcohol is poured off and the particles are rinsed with distilled water.
- the particles are then centrifuged and rinsed with water as above an additional three times.
- the particles are then dispersed in DMSO and centrifuged at 4000 rpm at 20° C. for ten minutes.
- the DMSO is poured off and the process is repeated another two times.
- Polyallylvalerolactone (PAVL; 100 mg (6700 g/mol; 19% allylvalerolactone and 81% valerolactone)) and hexanedithiol (1 —SH group per alkene) are dissolved in 1 mL dichloromethane.
- 2,2-Dimethoxy-2-phenylacetophenone (DMPA; 0.2 equivalents per alkene) is added and the solution is sprayed on to a 20 mL water bath containing 5% polyvinyl alcohol using a spray dryer.
- the spray-dried droplets and the homogenized mixture are irradiated at 365 nm-4 mW under stirring for 30 minutes.
- the mixture is stirred for 3 hours to allow the dichloromethane to evaporate.
- the mixture is then centrifuged at 4000 rpm at 10° C. for 10 minutes.
- the aqueous solution containing polyvinyl alcohol is poured off and the particles are rinsed with distilled water.
- the particles are then centrifuged and rinsed with water as above an additional three times.
- the particles are then dispersed in DMSO and centrifuged at 4000 rpm at 20° C. for ten minutes.
- the DMSO is poured off and the process is repeated another two times.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Materials For Medical Uses (AREA)
- Polyesters Or Polycarbonates (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epoxy Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
Description
- This application claims the benefit under 35 U.S.C § 119(e) of U.S. Provisional Patent Application Ser. No. 62/239,758, filed Oct. 9, 2015; U.S. Provisional Patent Application Ser. No. 62/281,631, filed Jan. 21, 2016; and U.S. Provisional Patent Application Ser. No. 62/313,013, filed Mar. 24, 2016, the disclosures of which are incorporated herein by reference in their entirety.
- The present disclosure teaches crosslinked particles (e.g., microparticles or nanoparticles) that are capable of storing and releasing drugs. The particles can release drug by degradation, erosion, diffusion, or a combination of mechanisms.
- Drug-eluting biodegradable nanoparticles can be used for a variety of biological applications, such as wound healing and arthritis treatment (see e.g., U.S. Pat. No. 7,935,782 and WO 2009/061854, the entire contents of which are hereby incorporated by reference in their entirety). However, it can be difficult to control particle size and morphology to achieve nanoparticles with reproducible results. Additionally, previous attempts to produce crosslinked particles were limited in size and therefore could only be loaded with a limited amount of a given drug. Smaller particles also tended to biodegrade more quickly than larger particles, and were therefore unable to provide sustained release of for a desired duration.
- Moreover, current drug delivery particles can suffer from a burst effect, wherein a substantial portion of a drug dispersed therein is released quickly released in a short period followed by a lower release rate. This has the effect of initially over dosing a patient and then later under dosing the patient.
- The present disclosure teaches particles (e.g., microparticles) that are crosslinked and can be used in vivo. The crosslinked particles can include a drug, and can release the drug when used in vivo. In some embodiments, the drug is released as the particle degrades. The microparticles can thus be used to release drugs at the site of wounds, or after surgical procedures to release therapeutic agents and help speed recovery. Additionally, the particles of the current disclosure can be used for the treatment of arthritis. For example, particles comprising arthritis therapeutics can be administered to the site of arthritis pain (e.g., by injection). In some embodiments, the present disclosure provides crosslinked particles such as microparticles that have reproducible size and morphology. In some embodiments, the present disclosure also provides particles that can release a drug for a sustained period of time (e.g., greater than one month) and which do not suffer from a burst effect (e.g., a release of substantial amount of drug soon after immersion in a solvent).
- In one aspect, the present disclosure provides a crosslinked degradable particle, comprising:
- a plurality of polyester backbones, wherein the plurality of polyester backbones are crosslinked via thioethers, triazoles, or amides; and
a drug dispersed within the crosslinked degradable particle. - In another aspect, the present disclosure provides a crosslinked degradable particle, comprising:
- a plurality of polymer backbones obtained from lactone monomer residues, wherein the plurality of polymer backbones are crosslinked via thioethers, triazoles, or amides; and
a drug dispersed within the crosslinked degradable particle, wherein the crosslinked degradable particle has a nominal diameter between 1 μm and 100 μm. - In another aspect, the present disclosure provides a crosslinked degradable particle, comprising:
- a plurality of polymer backbones obtained from lactone monomer residues, wherein the plurality of polymer backbones are crosslinked via thioethers, triazoles, or amides; and
a drug dispersed within the crosslinked degradable particle, wherein the crosslinked degradable particle has a nominal diameter between 1 micron and 100 microns. - In another aspect, the present disclosure provides a method of preparing a crosslinked degradable particle, comprising:
- combining a polyester containing a plurality of functional groups and a crosslinker to form a mixture; and
reacting the functional groups with crosslinkers to form a crosslinked degradable particle. - In another aspect, the present disclosure provides a method of preparing a crosslinked degradable particle, comprising:
- dissolving a polyester containing a plurality of allyl groups, a dithiol, and a photoinitiator in at least one solvent to form a solution;
emulsifying the solution in an aqueous phase to form an emulsion;
irradiating the emulsion with UV light to react the dithiol with two of the allyl groups to form a crosslink; and
evaporating at least a portion of the solvent from the emulsion. - In another aspect, the present disclosure provides a method of preparing a crosslinked degradable particle, comprising:
- dissolving a polyester containing a plurality of propargyl groups and a diazide in at least one solvent to form a solution;
emulsifying the solution in an aqueous phase to form an emulsion;
treating the emulsion to react the diazide with two of the propargyl groups to form a crosslink;
and
evaporating at least a portion of the solvent from the emulsion. - In another aspect, the present disclosure provides method of preparing a crosslinked degradable particle, comprising:
- dissolving a polyester containing a plurality of epoxide groups and a diamine in at least one solvent to form a solution;
emulsifying the solution in an aqueous phase to form an emulsion;
allowing the diamine to react with the epoxide groups to form a crosslink; and
evaporating at least a portion of the solvent from the emulsion. - In another aspect, the present disclosure provides a method of preparing a crosslinked degradable particle, comprising:
- dissolving a polyester containing a plurality of carboxylic acid groups and a diamine in at least one solvent to form a solution;
emulsifying the solution in an aqueous phase to form an emulsion;
treating the emulsion to react diamine to react with the carboxylic acid groups to form a crosslink; and
evaporating at least a portion of the solvent from the emulsion. - In another aspect, the present disclosure provides a method of reducing aggregation of a plurality of crosslinked degradable particles, comprising attaching a plurality of polyethylene glycol chains to an exterior of the plurality of crosslinked degradable particles.
- In another aspect, the present disclosure provides a method of dispersing a drug within a crosslinked degradable particle, comprising:
- swelling the crosslinked degradable particle with a solvent to form a swollen crosslinked degradable particle, wherein the solvent further comprises a drug dispersed therein; and
removing the crosslinked degradable particles from the solvent. - In another aspect, the present disclosure provides a method of preparing a crosslinked degradable implant, comprising:
- dissolving a polyester containing a plurality of functional groups and a crosslinker in at least one solvent to form a solution;
treating the solution to react the crosslinker with two of the functional groups to form a crosslink;
wherein the crosslinked degradable implant has a diameter of at least about 1 millimeter. - In another aspect, the present disclosure provides a method of controlling an average size of a distribution of crosslinked degradable particles, comprising:
- preparing a plurality of molds of uniform size and shape;
combining a polyester containing a plurality of functional groups and a crosslinker to form a mixture;
dispersing the mixture within the molds; and
treating the mixture to react the crosslinker with two of the functional groups to form a crosslink. - In another aspect, the present disclosure provides a method of controlling an average size of a distribution of crosslinked degradable particles, comprising:
- combining a polyester containing a plurality of functional groups and a crosslinker in at least one nonaqueous solvent to form an emulsion wherein the nonaqueous solvent comprises droplets of uniform size,
wherein the polyester and crosslinker, are dissolved in the nonaqueous solvent droplets; and
treating the emulsion to react the crosslinker with two of the functional groups to form a crosslink, wherein the particles are crosslinked while dissolved in the nonaqueous solvent. - In another aspect, the present disclosure provides a crosslinked degradable particle, formed by:
- forming a polyester containing a plurality of functional groups and a crosslinker to form a mixture; and
reacting the functional groups with crosslinkers to form a crosslinked degradable particle. - In another aspect, the present disclosure provides a method of treating a disease, comprising:
- administering to a subject in need thereof a therapeutically effective amount of the crosslinked degradable particle of the present disclosure containing the drug.
- In another aspect, the present disclosure provides use of a crosslinked degradable particle of the present disclosure for the treatment of a disease. In some embodiments, the crosslinked particle contains a drug.
- In another aspect, the present disclosure provides the use of a crosslinked degradable particle of the present disclosure in the manufacture of a medicament for the treatment of a disease. In some embodiments, the crosslinked particle contains a drug.
- In another aspect, the present disclosure provides a crosslinked degradable particle, comprising:
- a polyester backbone of the Formula I:
- wherein:
R1 is independently, at each occurrence, —H, or —C1-C6 alkyl;
R2 is independently, at each occurrence, —H, or —C1-C6 alkyl;
R3 is independently, at each occurrence, —H, or —C1-C6 alkyl;
a is 0, 1, or 2;
m is independently, at each occurrence, an integer between 1 and 1000, inclusive;
n is independently, at each occurrence, an integer between 1 and 1000, inclusive;
p is independently, at each occurrence, an integer between 0 and 5, inclusive;
q is independently, at each occurrence, an integer between 0 and 1000, inclusive;
r is independently, at each occurrence, an integer between 0 and 1000, inclusive; and
t is independently, at each occurrence, an integer between 0 and 5, inclusive. - In another aspect, the present disclosure provides a crosslinked degradable particle,
- a polyester backbone of the Formula II:
- wherein:
R1 is independently, at each occurrence, —H, or —C1-C6 alkyl;
R2 is independently, at each occurrence, —H, or —C1-C6 alkyl;
R3 is independently, at each occurrence, —H, or —C1-C6 alkyl;
a is 0, 1, or 2;
m is independently, at each occurrence, an integer between 1 and 1000, inclusive;
n is independently, at each occurrence, an integer between 1 and 1000, inclusive;
p is independently, at each occurrence, an integer between 0 and 5, inclusive;
q is independently, at each occurrence, an integer between 0 and 1000, inclusive;
r is independently, at each occurrence, an integer between 0 and 1000, inclusive; and
t is independently, at each occurrence, an integer between 0 and 5, inclusive. - In another aspect, the present disclosure provides a crosslinked degradable particle,
- a polyester backbone of the Formula III:
- wherein:
R1 is independently, at each occurrence, —H, or —C1-C6 alkyl;
R2 is independently, at each occurrence, —H, or —C1-C6 alkyl;
R3 is independently, at each occurrence, —H, or —C1-C6 alkyl;
a is 0, 1, or 2;
m is independently, at each occurrence, an integer between 1 and 1000, inclusive;
n is independently, at each occurrence, an integer between 1 and 1000, inclusive;
p is independently, at each occurrence, an integer between 0 and 5, inclusive;
q is independently, at each occurrence, an integer between 0 and 1000, inclusive;
r is independently, at each occurrence, an integer between 0 and 1000, inclusive; and
t is independently, at each occurrence, an integer between 0 and 5, inclusive. - In another aspect, the present disclosure provides a crosslinked degradable particle,
- a polyester backbone of the Formula IV:
- wherein:
R1 is independently, at each occurrence, —H, or —C1-C6 alkyl;
R2 is independently, at each occurrence, —H, or —C1-C6 alkyl;
R3 is independently, at each occurrence, —H, or —C1-C6 alkyl;
a is 0, 1, or 2;
m is independently, at each occurrence, an integer between 1 and 1000, inclusive;
n is independently, at each occurrence, an integer between 1 and 1000, inclusive;
p is independently, at each occurrence, an integer between 0 and 5, inclusive;
q is independently, at each occurrence, an integer between 0 and 1000, inclusive;
r is independently, at each occurrence, an integer between 0 and 1000, inclusive; and
t is independently, at each occurrence, an integer between 0 and 5, inclusive. - In another aspect, the present disclosure provides a crosslinked degradable particle, a polyester backbone of the Formula V:
- wherein:
R1 is independently, at each occurrence, —H, or —C1-C6 alkyl;
R2 is independently, at each occurrence, —H, or —C1-C6 alkyl;
R3 is independently, at each occurrence, —H, or —C1-C6 alkyl;
a is 0, 1, or 2;
m is independently, at each occurrence, an integer between 1 and 1000, inclusive;
n is independently, at each occurrence, an integer between 1 and 1000, inclusive;
p is independently, at each occurrence, an integer between 0 and 5, inclusive;
q is independently, at each occurrence, an integer between 0 and 1000, inclusive;
r is independently, at each occurrence, an integer between 0 and 1000, inclusive; and
t is independently, at each occurrence, an integer between 0 and 5, inclusive. - In another aspect, the present disclosure provides a crosslinked degradable particle, comprising:
- a polyester backbone of the Formula VI:
- wherein:
R1 is independently, at each occurrence, —H, or —C1-C6 alkyl;
R2 is independently, at each occurrence, —H, or —C1-C6 alkyl;
R3 is independently, at each occurrence, —H, or —C1-C6 alkyl;
a is 0, 1, or 2;
m is independently, at each occurrence, an integer between 1 and 1000, inclusive;
n is independently, at each occurrence, an integer between 1 and 1000, inclusive;
p is independently, at each occurrence, an integer between 0 and 5, inclusive;
q is independently, at each occurrence, an integer between 0 and 1000, inclusive;
r is independently, at each occurrence, an integer between 0 and 1000, inclusive; and
t is independently, at each occurrence, an integer between 0 and 5, inclusive. - In another aspect, the present disclosure provides a crosslinked degradable particle, comprising:
- a polyester backbone of the Formula VII:
- wherein:
R is independently, at each occurrence, —H, or —C1-C6 alkyl
R1 is independently, at each occurrence, —H, or —C1-C6 alkyl;
R2 is independently, at each occurrence, —H, or —C1-C6 alkyl;
R3 is independently, at each occurrence, —H, or —C1-C6 alkyl;
a is 0, 1, or 2;
m is independently, at each occurrence, an integer between 1 and 1000, inclusive;
n is independently, at each occurrence, an integer between 1 and 1000, inclusive;
p is independently, at each occurrence, an integer between 0 and 5, inclusive;
q is independently, at each occurrence, an integer between 0 and 1000, inclusive;
r is independently, at each occurrence, an integer between 0 and 1000, inclusive; and
t is independently, at each occurrence, an integer between 0 and 5, inclusive. - The crosslinked particles (e.g., macroparticles, microparticles or nanoparticles) of the present disclosure can have uniform size and shape along with other characteristics such as stability. This can allow the crosslinked particles of the present disclosure to be used in medical settings with high reproducibility and reliability. Additional features and advantages of the present disclosure will be apparent to one of skill in the art and are set forth in the Detailed Description, below.
-
FIG. 1A shows a photo of polycaprolactone (PCL), polyvalerolactone/polyallylvalerolactone copolymer (PVL-co-PAVL) microparticles at a scale of about 1500 μm. -
FIG. 1B shows photo of PCL, PVL-co-PAVL microparticles at a scale of about 400 μm. -
FIG. 1C shows a photo of PCL, PVL-co-PAVL microparticles at a scale of about 600 μm. -
FIG. 1D shows a photo of PCL, PVL-co-PAVL microparticles at a scale of about 20 μm, along with a size distribution scheme. -
FIG. 2A shows a photo of PVL-co-PAVL microparticles at a scale of about 1500 μm. -
FIG. 2B shows photo of PVL-co-PAVL microparticles at a scale of about 400 μm. -
FIG. 2C shows a photo of PVL-co-PAVL microparticles at a scale of about 600 μm. -
FIG. 2D shows a photo of PVL-co-PAVL microparticles at a scale of about 20 μm, along with a size distribution scheme. -
FIG. 3A shows a schematic of self-assembly of amphiphilic block copolymers into micellar structures. -
FIG. 3B shows a schematic of encapsulation of polymers and crosslinkers of the present disclosure into the lipid phase of a lipid-water emulsion. -
FIG. 4 shows a general schematic for loading drugs into particles of the present disclosure -
FIG. 5 shows a DLS plot of crosslinked mPEG-b-PVL-co-PAVL nanoparticles in water. -
FIG. 6 shows a DLS plot of crosslinked mPEG-b-PVL-co-PAVL nanoparticles in dimethylsulfoxide (DMSO). -
FIG. 7 shows a DLS plot of crosslinked mPEG-b-PVL-co-PAVL nanoparticles in THF. -
FIG. 8 shows a DLS plot of non-crosslinked mPEG-b-PVL-co-PAVL nanoparticles in water. -
FIG. 9A shows a histogram and an image of 25% PVL-co-PAVL microparticles after crosslinking. -
FIG. 9B shows a histogram and microscope image of the same microparticles after a DMSO washing step. -
FIG. 9C shows a histogram and microscope image of the particles after an ethanol washing step. -
FIG. 9D shows a histogram and microscope image of the particles after swelling in THF. -
FIG. 10A shows a 1HNMR spectrum of PVL-co-PAVL polymer. -
FIG. 10B shows a gel permeation chromatography plot of the PVL-co-PAVL polymer backbone comprising 6% PAVL, 10% PAVL, and 25% PAVL. -
FIG. 11A shows a microscope image of mPEG-b-PVL-co-PAVL macroparticles (80:20) at a resolution of about 1 mm. -
FIG. 11B shows a microscope image of mPEG-b-PVL-co-PAVL macroparticles (80:20) at a resolution of about 200 μm. -
FIG. 11C shows a first microscope image of mPEG-b-PVL-co-PAVL macroparticles (80:20) at a resolution of about 10 μm. -
FIG. 11D shows a second microscope image of mPEG-b-PVL-co-PAVL macroparticles (80:20) at a resolution of about 10 μm. -
FIG. 12 shows a microscope micrograph of non-crosslinked microparticles in water. -
FIG. 13 shows the drug loading capacity of macroparticles, according to an embodiment of the disclosure. -
FIG. 14 shows a DSC plot of microparticles loaded with curcumin, paclitaxel, triamcinolone acetonide, triamcinolone hexacetonide, and without drug. -
FIG. 15 shows FTIR spectra of microparticles of the present disclosure loaded with curcumin, paclitaxel, triamcinolone acetonide, triamcinolone hexacetonide, and without drug. -
FIG. 16 shows a microscopic image of microparticle flakes after being dried overnight. -
FIG. 17 shows the release profile of curcumin release from microparticle flakes. -
FIG. 18A shows curcumin-loaded particles dissolved in water containing 1% tween after being dried in THF with 25% PEG as a co-solvent. -
FIG. 18B shows a close-up view of curcumin-loaded particles dissolved in water containing 1% tween after being dried in THF with 25% PEG as a co-solvent. -
FIG. 19A shows a microscope image of microparticle flakes in water after drying with 2.5% PEG as a co-solvent. -
FIG. 19B shows a microscope image of microparticle flakes in THF after drying with 2.5% PEG as a co-solvent. -
FIG. 19C shows a microscope image of microparticle flakes in water after drying with 5% PEG as a co-solvent. -
FIG. 19D shows a microscope image of microparticle flakes in THF after drying with 5% PEG as a co-solvent. -
FIG. 20A shows an aqueous solubility plot of triamcinolone acetonide in the presence ofsurfactants Tween 80 and SDS. -
FIG. 20B shows an aqueous solubility plot of triamcinolone hexacetonide in the presence ofsurfactants Tween 80 and SDS. -
FIG. 20C shows an aqueous solubility plot of paclitaxel in the presence ofsurfactants Tween 80 and SDS. -
FIG. 21 shows a 7-day release profile of curcumin from a macroparticle. -
FIG. 22 shows a 20-day curcumin release profile from a 13-mg and 12-mg macroparticle. -
FIG. 23 shows a 6-day release profile of triamcinolone hexacetonide from two macroparticles. -
FIG. 24 shows a 20-day triamcinolone hexacetonide release profile from a 13.3-mg and 9.2-mg macroparticle. -
FIG. 25 shows a comparison of the release profiles of curcumin, triamcinolone hexacetonide (TAH), triamcinolone acetonide (TAA), and paclitaxel (PTX). -
FIG. 26 shows a microscope micrograph of the photolithography template. -
FIG. 27A shows a gelatin template with raised pegs under a microscope. -
FIG. 27B shows a first microscope image of microparticles prepared by the gelatin hydrogel template method. -
FIG. 27C shows a second microscope image of microparticles prepared by the gelatin hydrogel template method. -
FIG. 28A shows a DSC plot of a control microparticle with no crosslinking. -
FIG. 28B shows a DSC plot of a microparticle with 50% crosslinking. The DSC plot shows about 30% of crystallinity. -
FIG. 28C shows a DSC plot of a microparticle with 100% crosslinking. -
FIG. 29A shows a DSC plot of a control microparticle with no crosslinking. -
FIG. 29B shows a DSC plot of a microparticle with 50% crosslinking. The DSC plot shows less than 1% crystallinity. -
FIG. 29C shows a DSC plot with 100% crosslinking. - The present disclosure provides crosslinked particles (e.g., microparticles, microparticles or nanoparticles) that can be used in medical applications (e.g., to locally release drugs). In some embodiments, the present disclosure provides microparticles comprising a polyester backbone that can be crosslinked via functional groups disposed along the polyester backbone in the presence of an appropriate crosslinking reagent.
- In some embodiments, the polyester backbones are crosslinked via thioethers. The polyester backbones can be crosslinked via triazoles. The polyester backbones can be crosslinked via amides. The polyester backbones can be crosslinked via amines (e.g., via an amine-epoxide reaction). The polyester backbones can be crosslinked by a tetrazine-trans-cyclooctene reaction. The polyester backbones can be crosslinked by a thiol-norbornene reaction. The polyester backbones can be crosslinked by an amine-carbonyl (e.g., aldehyde or ketone) reductive amination. The particles can be biodegradable.
- The microparticles of the present disclosure can have a diameter between about 1 μm and about 999 μm, including all ranges and subranges therebetween, and more preferably, the microparticles can have a diameter between about 1 μm and about 100 μm, including all ranges and subranges therebetween. In some embodiments, the microparticles of the present disclosure can have a diameter between about 5 μm and about 30 μm, including all ranges and subranges therebetween (e.g., between about 7 μm and about 15 μm or about 10 μm).
- The macroparticles of the present disclosure can have a mean diameter greater than about 1000 μm.
- In some embodiments, the drug dispersed within a microparticle of the disclosure can be triamcinolone, triamcinolone acetonide, triamcinolone hexacetonide, and paclitaxel. In some embodiments other compounds such as curcumin can be dispersed within the particles (for instance, curcumin can be used to more easily visualize release kinetics). In some embodiments, curcumin can be used as a surrogate for a drug. In some embodiments, the drug is covalently bonded to the particle. In some embodiments, the drug is contained within the particle by noncovalent interactions. In some embodiments, the particle releases the drug over a period of at least one week in an aqueous environment (e.g., at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 2 months, at least 3 months, at least 4 months, at least 5 months, or at least 6 months). In some embodiments, the particle degrades as it releases the drug.
- In some embodiments, the polyester backbone comprises polyvalerolactone (PVL), polycaprolactone (PCL), polylactic acid (PLA), polyglycolic acid (PGC), or a combination thereof. In some embodiments, the particle is a macroparticle. In some embodiments, the particle is a microparticle. In some embodiments, the particle is a nanoparticle. In some embodiments, the polyester backbone further comprises polyethylene glycol (PEG). In some embodiments, the polymer backbone is obtained from a monomer residue comprising valerolactone (e.g., polyvalerolactone), caprolactone (e.g., polycaprolactone), lactic acid (e.g., polylactic acid), glycolic acid (e.g., polyglycolic acid), or a combination thereof. In some embodiments, the lactone monomer is selected from the group consisting of lactic acid, glycolic acid, valerolactone, caprolactone, lactide, or a combination thereof.
- In one or more embodiments, any of the valerolactone, caprolactone, lactic acid, lactide, or glycolic acid is functionalized with a functional group. In some embodiments, the functional group can be selected from an allyl group, a propargyl group, or a carboxylic acid group (e.g., the functional groups can be allyl lactide, allyl valerolactone and the like). Alternatively, the functional group can be a trans-cyclooctene, norbornene, or a carbonyl group (e.g., an aldehyde or ketone). Alternatively, the functional group can be a thiol group, an amine, or a tetrazine.
- In one or more embodiments, the polyester and crosslinker are combined in a solvent to form the mixture. In some embodiments of any of the above methods, particles of the disclosure are made by emulsifying the mixture, wherein the polyester and the crosslinker are in the same phase. In some embodiments, the methods further comprise evaporating at least part of the solvent prior to reacting the functional groups with the crosslinker. In some embodiments, the functional group of the polyester backbone comprises an olefin group (e.g., an allyl group), an alkynyl group (e.g., a propargyl group), an epoxy group, a carboxylic acid group, or a carboxylic acid derivative (e.g., an ester or amide).
- In some embodiments, particles (e.g., microparticles) of the present disclosure can be formed by electrospraying. In some embodiments, particles (e.g., microparticles) of the present disclosure can be formed by spray-drying.
- In some embodiments, the crosslinker comprises a dithiol group. In some embodiments, the dithiol group forms a thioether with an olefin functional group on the polyester backbone. In some embodiments, the crosslinker comprises a diazide. In some embodiments, the diazide forms a triazole with a propargyl functional group on the polyester backbone. In some embodiments, the crosslinker comprises a diamine. In some embodiments, diamine forms a β-hydroxy amine with an epoxide functional group on the polyester backbone. In some embodiments, the diamine forms an amide with a carboxylic acid functional group on the polyester backbone.
- In some embodiments, the step of treating the emulsion comprises heating the emulsion or adding a catalyst (e.g., a cyclization catalyst such as a copper or rhodium salt such as a copper (I) salt). In some embodiments, the catalyst for forming an amide crosslinker is an amide coupling catalyst such as N,N′-dicyclohexylcarbodiimide or diisopropylcarbodiimide. In some embodiments, the polyester backbones comprise polyvalerolactone, polycaprolactone, polylactic acid, polyglycolic acid, or a combination thereof. In some embodiments, the polyester backbones are crosslinked by thioethers, triazoles, or amides. For example, in any of the above-embodiments, the act of combining a polyester with a plurality of functional groups and a crosslinker can further comprise also adding an initiator (e.g., a photoinitiator) and/or a catalyst (e.g., a copper catalyst).
- In some embodiments of any of the above-methods, the solution (e.g., the emulsion in which the particles are formed further comprises an initiator (e.g., a photoinitiator). In some embodiments, the method of treating the solution comprises irradiating the photoinitiator with ultraviolet light. In some embodiments, a dithiol group forms a thioether with an olefin functional group on the polyester backbone. In some embodiments, the thioether is formed by a radical reaction. In some embodiments, the radical reaction is initiated by a photoinitiator and treatment with ultraviolet light. In some embodiments, the crosslinker comprises a diazide. In some embodiments, the diazide forms a triazole with a propargyl functional group on the polyester backbone. In some embodiments, the triazole is formed in the presence of a copper (I) catalyst.
- The articles “a” and “an” are used in this disclosure to refer to one or more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.
- The term “and/or” is used in this disclosure to mean either “and” or “or” unless indicated otherwise.
- “Alkyl” refers to a straight or branched chain saturated hydrocarbon. C1-C6alkyl groups contain 1 to 6 carbon atoms. Examples of a C1-C6alkyl group include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, isopropyl, isobutyl, sec-butyl and tert-butyl, isopentyl and neopentyl.
- The term “treating” with regard to a subject, refers to improving at least one symptom of the subject's disorder. Treating includes curing, improving, or at least partially ameliorating the disorder.
- The term “disorder” is used in this disclosure to mean, and is used interchangeably with, the terms disease, condition, or illness, unless otherwise indicated.
- The term “administer”, “administering”, or “administration” as used in this disclosure refers to either directly administering a disclosed particle (e.g., a microparticle) or pharmaceutically acceptable salt of the disclosed particle or a composition to a subject.
- As used herein the term “backbone” is understood to mean a polyester chain The polyester backbones of the present disclosure can be crosslinked to form particles such as microparticles or nanoparticles as disclosed herein.
- As used herein, a “particle” is a discrete unit comprising polymer backbones as set forth herein that has been crosslinked. The particle can be a nanoparticle, a microparticle, or a macroparticle. The particle may include a drug dispersed therein.
- A “nanoparticle” is understood as a crosslinked particle of the present disclosure with a diameter of between about 1 nm and about 999 nm, including all size ranges and subranges therebetween.
- A “microparticle” as used herein is understood as a crosslinked particle of the present disclosure with a diameter of between about 1 μm (1,000 nm) and about 999 μm including all size ranges and subranges therebetween. As noted above, the microparticles can have a diameter between about 1 μm and about 100 μm, including all ranges and subranges therebetween. In some embodiments, the microparticles of the present disclosure can have a diameter between about 5 μm and about 30 μm, including all ranges and subranges therebetween (e.g., between about 7 μm and about 15 μm or about 10 μm).
- A “macroparticle” as used herein is understood as a crosslinked particle of the present disclosure with a diameter of between about 1 mm (1,000 μm) and about 100 mm, including all size ranges and subranges therebetween. As used herein, a “macroparticle” can be a device or implant. In some embodiments, a single macroparticle can be visible to the naked eye. In some embodiments, macroparticles are referred to as “cylinders.”
- As used herein, a “drug” is any small molecule therapeutic agent. A drug can be, without limitation, a steroid such as triamcinolone, triamcinolone acetonide, triamcinolone hexacetonide, or paclitaxel. A “drug” can also include a visualizing agent such as curcumin.
- A “patient” or “subject” is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon, or rhesus.
- Particles of the present disclosure can be used in medical applications. For example, particles can be used to heal a wound (e.g., as antiseptics). A wound is understood as an injury to living tissue. Wounds can be caused by cuts, blows, or impacts. Wounds can also be the result of a surgery. Accordingly, in some embodiments, the compounds of the present disclosure can be used to help heal wounds after a surgery. The particles of the present disclosure can be injected (e.g., with a syringe). In some embodiments, the particles of the present disclosure are administered during a surgery and remain after the surgery (e.g., for a period of 1-6 months).
- The definition of the crosslinking density of the particle is based on the percentage of the pendant functionality (e.g., allyl, propargyl, or epoxy) of the linear polymer precursor (e.g., polyester) (van der Ende, A. E., et al. (2008) J. Am Chem. Soc. 130, p. 8706). As used herein, the term “cross-linking density” refers to the proportion of functionalized monomer (e.g., allyl valerolactone) used in preparing a polymer such as a copolymer, expressed as a weight percentage of monomers used. For example, if 4% allylvalerolactone and 96% valerolactone are used (by weight) to prepare a polymer backbone, then the crosslinking density of the resulting particle is understood to be 4%. Actual crosslinking density can be determined by analytical techniques including, but not limited to, infrared spectroscopy, pyrolysis gas chromatography, and nuclear magnetic resonance.
- The crosslinking densities of the particles of the present disclosure can be between 1% and 100%, inclusive. In some embodiments, the crosslinking density is about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%.
- As used herein, the term “VL” is understood to mean valerolactone.
- Microparticles of the present disclosure can be prepared by dissolution of functionalized polyesters in a solvent along with a crosslinker and subsequent crosslinking of the mixture. The resulting product is a plurality of crosslinked microparticles. As set forth in Examples 3 and 4, microparticles comprising PCL with (polyallylvalerolactone-polyvalerolactone) PAVL-PVL (Example 3) and PAVL-PVL (Example 4) were crosslinked using hexanedithiol in the presence of 2,2-dimethoxy-2-phenylacetophenone (DMPA) by irradiation with ultraviolet (UV) light. The microparticles thus produced (see e.g.,
FIGS. 1A-2D ) were in insoluble in dimethyl sulfoxide (DMSO). This demonstrates that the particles produced as described herein are discrete units that are structurally different from the polymeric (e.g., polyester) precursors (or backbones). Without wishing to be bound by theory, crosslinking affords structural integrity to the particles. - In contrast to the crosslinked particles, Comparative Examples 3 and 4 demonstrate microparticles that are produced in the absence of a crosslinker. Comparative Examples 3 and 4 combine PCL with PAVL-PVL (Comparative Example 3) and PAVL-PVL (Comparative Example 4) with UV light in the absence of a crosslinker (e.g., hexanedithiol). Because no crosslinking can occur in the absence of a crosslinker, no microparticles were formed. Accordingly, the polyesters remained intact and were soluble in DMSO. Therefore, in some embodiments, it is necessary to crosslink the polyesters described herein in order to form microparticles and in order to ensure desired characteristics such as stability and size.
- Without wishing to be bound by theory, polymer backbones that are incapable of crosslinking (e.g., PLGA polymers) can be dependent upon micelle concentration in order to form. For example, as set forth in
FIG. 3A , amphiphilic block copolymers can self-assemble into micellar structures. However, such micelles can fall apart below the critical micelle concentration (CMC). - In contrast, as set forth in
FIG. 3B , compounds of the present disclosure comprise functionalized polymers and reactive crosslinkers and are covalently crosslinked in a particle (e.g., nanoparticle or microparticle) structure. Thus the particles of the present disclosure remain intact regardless of concentration and are not dependent upon the critical micelle concentration. - According to embodiments of the present disclosure, the microparticles are crosslinked.
Schemes 1 through 3 below show general routes to the crosslinked particles of the present disclosure. - As shown in
Scheme 1, a polyester comprising polyvalerolactone and polyallylvalerolactone (1) can be crosslinked in using a disulfide (2) in the presence of a radical initiator (e.g., a photoinitiator such as DMPA). The ratio of DMPA per allyl group can be adjusted to control the properties of the resulting microparticle (e.g., to produce more or less crosslinking). For instance, in some embodiments 0.2 equivalents of DMPA per allyl group can be added. In some embodiments, one thiol group in (2) can be added for each allyl group in (1). Upon treatment of the mixture of (1) and (2) with UV light (e.g., 365 nm), the allyl groups can crosslink with the thiol groups of the crosslinker to produce a crosslinked microparticle (3). As used inScheme 1, the values for d, e, and f can each independently be any integer between 1 and 1000, inclusive. - As shown in
Scheme 2, a polyester comprising polyvalerolactone and polyallylvalerolactone (4) can be crosslinked in using a disulfide (5) in the presence of a radical initiator (e.g., a photoinitiator such as DMPA). The ratio of DMPA to allyl groups can be adjusted to control the properties of the resulting microparticle (e.g., to adjust the rate of crosslinking and to produce more or less crosslinking). For instance, in some embodiments 0.2 equivalents of DMPA per allyl group can be added. In some embodiments, one thiol group in (5) can be added for each allyl group in (4). Upon treatment with UV light (e.g., 365 nm), the allyl groups can crosslink with the thiol groups of the crosslinker to produce a crosslinked microparticle (6). As used inScheme 2, the values for d, e, and f can each independently be any integer between 1 and 1000, inclusive. - In some embodiments, crosslinking can take place by the reaction of an amine group with a carbonyl (e.g., a reductive amination). As shown below in
Scheme 3, a polymer backbone functionalized with carbonyl groups (e.g., aldehydes or ketones such as methyl ketones) can react with a diamine to form carbon-nitrogen bonds. Such reactions can be facilitated by a reducing agent (e.g., sodium cyanoborohydride), optionally in the presence of an acid (e.g., acetic acid). -
Scheme 3 shows a reductive amination between a diamine (8) and a polymer backbone that is functionalized with an aldehyde and a methyl ketone (7) to produce a crosslinked polymer (9). One of skill in the art will understand that it is possible to carry out a crosslinking reductive amination using, for instance, only aldehydes, or only ketones (e.g., phenyl ketones, ethyl ketones, and the like), or a mixture of both aldehydes and ketones. As set forth inScheme 3, the variables d, e, and f can be integers between 1 and 1000, inclusive. - In some embodiments, the microparticles of the present disclosure can be made from functionalized polymer backbones. That is, as set forth below, the polymer backbones can be functionalized with, for instance, olefin (e.g., allyl), alkynyl (e.g., propargyl), or epoxy groups. Thus, embodiments the particles of the present disclosure are not made entirely from unfunctionalized poly(lactic-co-glycolic acid) (PLGA), which historically can be difficult to functionalize. However, in some embodiments, unfunctionalized PLGA could be incorporated into portions of a copolymer backbone that also includes other functionalized polymers in the copolymer backbone.
- Functionalization of the polymers of the present disclosure can enable one of skill in the art to customize the features of the particles. For example, as set forth below, the adjustment of the ratios and types of crosslinker and polymer can allow for alterations in, e.g., porosity, drug loading and release, and rates of degradation.
- A variety of different polyester backbones can be used to form particles of the present disclosure. For example, in some embodiments the polyester backbones are made from polycaprolactone (PCL). In some embodiments, the polyester backbones are made from polyvalerolactone (PVL). In some embodiments, the PCL or PVL can be functionalized with an allyl group to produce polyallylcaprolactone (PACL) or polyallylvalerolactone (PAVL). In some embodiments, polyesters of the present disclosure are copolymers comprising two or more different monomers. For example, polyesters can comprise PVL and PAVL; PCL and PACL; PVL and PACL; or PCL and PAVL. In some embodiments, polyesters of the present disclosure can further comprise polylactic acid and/or polyglycolic acid. In some embodiments, any of the polyvalerolactone, polycaprolactone, polylactic acid, or polyglycolic acid can be functionalized with a functional group. For example, any of the polyvalerolactone, polycaprolactone, polylactic acid, or polyglycolic acid can further include an ally group, a propargyl group, or a carboxylic acid (or carboxylic acid derivative) disposed along the polymer backbone. The functional group can be used to crosslink the polymer backbone with another polymer backbone. In some embodiments, the copolymers of the disclosure can be block copolymers or random copolymers.
- For instance, in one embodiment, the polyester backbone can comprise a copolymer of polyvalerolactone and polyallylvalerolactone (PVL-co-PAVL):
- The values of m and n are integers and can each independently fall between about 1 and 1,000. For instance, when n is about 48 and m is about 15, the molecular weight is about 7,000 g/mol. When n is about 128 and m is about 14, the molecular weight is about 14,760 g/mol.
- In another embodiment, the polyester backbone can comprise a stabilizer (e.g., a PEG stabilizer). For example, a polyester backbone can comprise mPEG2k-b-PVL-co-PAVL:
- The values of m, n and q are each integers and can each independently fall between about 1 and 1,000. For example when q is about 50, n is about 40, and m is about 9, the molecular weight of the polyester is about 7,500 g/mol.
- In another embodiment, the polyester backbone can comprise polyallyl lactide. The polyallyl lactide can be formed from polymerization of allyl lactide. For example, a polyester backbone can comprise a copolymer of polyvalerolactone and polyallyllactide (PVL-co-PAL):
- The polyesters of the present disclosure can be prepared using a variety of different suitable monomers. For example, valerolactone can be used to prepare polyvalerolactone, and allylvalerolactone can be used to prepare polyallylvalerolactone. Similarly, caprolactone can be used to prepare polycaprolactone, and allylcaprolactone can be used to prepare polyallylcaprolactone. In some embodiments, lactic acid, glycolic acid, allyl lactide, and combinations thereof can be used as monomers to prepare the polyesters disclosed herein. One of skill in the art will readily understand how to select an appropriate monomer to arrive at a desired polyester backbone.
- In any of the embodiments disclosed herein, the polyesters of the present disclosure can further comprise polyethyleneglycol (PEG). In some embodiments, the PEG can connect two different sections of polyester. That is, the PEG can be dispersed between ester-containing portions of the polyester backbone. Alternatively, in some embodiments, the PEG can be attached at the end of the polymer (i.e., the PEG can comprise a terminal portion of the polymer). Thus, in some embodiments, the PEG is found primarily towards the outside of the microparticles.
- In some embodiments, crosslinked polymers of the present disclosure can further include additional polymers entangled therein. In some embodiments, compositions of the present disclosure can include PVL and/or PAVL polymer backbones crosslinked together. In some embodiments, the present disclosure includes PVL and/or PAVL polymer backbones crosslinked together with PCL entangled therein. In some embodiments, the present disclosure can include PVL and/or PAVL polymerized onto PCL backbones, or PVL and or PAVL portions crosslinked together. In some embodiments, the present disclosure can include PVL and/or PAVL and PEG polymer backbones crosslinked together.
- The present disclosure provides for a number of different crosslinkers and crosslinking strategies that can be used to crosslink and form the microparticles described herein. In one embodiment, crosslinking can take place in the presence of a radical initiator (e.g., a photoinitiator). In some embodiments, the crosslinking reaction can be a radical thiol-ene reaction. For example, as set forth in Examples 3 and 4, a photoinitiator (i.e., 2,2-dimethoxy-2-phenylacetophenone) can be used to crosslink a hexanedithiol crosslinker with the allyl functional groups present on a PAVL-PVL polymer backbone. One of skill in the art will recognize that a photoinitiator can be used create radicals (e.g., in the presence of UV light). In some embodiments, photoinitiators do not require heat to produce radicals. The radicals thus created can initiate a thiol-ene chain reaction between the thiols on the hexanedithiol with the olefin functionality (e.g., of the ally group) of PAVL to crosslink the polyester backbones and produce particles (e.g., microparticles or nanoparticles). One of skill in the art will appreciate that additional radical initiators can be used to initiate a crosslinking reaction such as the thiol-ene reaction. For example, other radical initiators can include, without limitation, thermal initiators, halogens such as chlorine, bromine, and iodine, azo compounds such as azobisisobutyronitrile (AIBN), and organic peroxides such as di-tert-butyl peroxide and benzoyl peroxide.
- In some embodiments, the radical initiator can be a drug itself. For instance, using a drug that can form radicals to initiate a crosslinking chain reaction can simultaneously lead to the creation of crosslinked particles (e.g., microparticles) as well as ensure that the drug is dispersed within the particles. In some embodiments, a drug can be an initiator for crosslinking of the polymer backbones (e.g., polyester backbone) to form a particle of the present disclosure. Additionally, the radical initiators of the present disclosure need not be photoinitiators. In some embodiments, the radical initiators used herein can create radicals, for instance, thermally (e.g., upon heating). The amount of time necessary to crosslink polyesters using UV exposure can be, for instance, between about 1 and about 60 minutes. For example, an emulsion of the present disclosure can be exposed to UV light for about 1, about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, or about 60 minutes.
- Additionally, crosslinking can take place via the formation of a triazole from the reaction between an alkyne group and an azide group. For example, polyesters of the present disclosure can be functionalized with an alkynyl group (e.g., a propargyl group). The alkynyl group can react in the presence of a diazide (e.g., 1,6-hexanediazide). The alkynyl groups on the polyester chains can react to form triazoles with the crosslinkers (e.g., via the azide-alkyne Huisgen cycloaddition), thus creating particles (e.g., microparticles). One of skill in the art will understand that this reaction can be carried out in the presence of a catalyst. For instance, the cycloaddition reaction can be carried out in the presence of a copper (I) salt (e.g., cuprous bromide or cuprous iodide). In some embodiments, the reaction can be carried out in the presence of a copper (II) salt (e.g., copper (II) sulfate) and a reducing agent (e.g. sodium ascorbate) to produce copper (I) in situ. In some embodiments, the cycloaddition reaction takes place in the absence of a catalyst. For example, in some embodiments, the cycloaddition reaction can take place upon heating the mixture.
- In some embodiments, crosslinking can take place via the formation of amide bonds (—C(O)NR—). For example, in some embodiments crosslinking can be effected by amide formation between a polyester of the disclosure that has been functionalized with a carboxylic acid group (or a carboxylic acid derivative) and a diamine (e.g., 1,6 hexanediamine). The amide formation can take place in the presence of a peptide coupling catalyst such as N,N′-Dicyclohexylcarbodiimide (“DCC”), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (“HBTU”), or 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (“HATU”). In some embodiments, the amide coupling reagent can be added after the carboxylic acid group and the diamine are dissolved in the same phase. One of skill in the art will further recognize that it is possible to form amide linkages in the absence of a peptide coupling reagent. For example, amide bonds can be formed by heating a mixture of carboxylic acid groups (e.g., in the presence of an acid). Alternatively, amide bonds can be formed between amines and carboxylic acid derivatives. For example, a crosslinking amide bond can be formed by treatment of an ester or non-crosslinked amide with a crosslinking amine group.
- In some embodiments, crosslinking can take place via the formation of a β-hydroxy amine. For example, crosslinking can take place between an epoxide group disposed along a polyester backbone as described herein and an amine moiety. The diamines can react with the epoxides (e.g., nucleophilic attack) to form carbon-nitrogen bonds. One of skill in the art will understand that the regiochemistry of the O-hydroxy amine-forming reaction can be controlled by the reaction conditions (e.g., use of acid or basic catalysis). For example, one can influence whether a monosubstituted epoxide opens at the terminal position by using basic catalysis. Thus, as shown in Scheme 4, below, one of skill in the art will understand that multiple outcomes of amine-epoxy reaction are possible in the reaction between an epoxide-functionalized backbone (10) and a diamine (11) to arrive at a crosslinked particle (12):
- In some embodiments, the nucleophile can be a molecule wherein the nucleophilic site has an atom with an additional lone pair of atoms alpha to the nucleophilic atom (e.g., can be an “alpha effect” nucleophile). For example, the nucleophilic portion of the crosslinker can be a hydrazine, a peroxide, or a hydroxylamine.
- In some embodiments, particles (e.g., microparticles) of the present disclosure can be crosslinked by a reaction between a tetrazine and a trans-cyclooctene. For example, crosslinking can take place as set forth in
Scheme 5, below. One of skill in the art will understand that a variety of different regiochemistries is possible with a tetrazine-trans-cyclooctene reaction. - As set forth in
Scheme 5, treatment of a trans-cyclooctene functionalized backbone (13) can be crosslinked with a ditetrazine (14). The tetrazine group can react with the trans-olefin of the cyclooctene group (e.g., a Diels-Alder cycloaddition followed by elimination of nitrogen gas). As set forth above inScheme 5, the regiochemistry of tetrazine addition can vary. The flexibility in regiochemical crosslinking is also shown in Formula V. One of skill in the art will understand that Formula V shows that the crosslinking reaction is not limited to a specific regiochemistry (e.g., the trans-cyclooctene can be attached to the polymer backbone at different positions than the position shown). - In some embodiments, particles (e.g., microparticles) of the present disclosure can be crosslinked by a reaction between a thiol and a norbornene. For example, crosslinking can take place as set forth in
Scheme 6, below. One of skill in the art will understand that a variety of different regiochemistries is possible with a thiol-norbornene reaction, and the present disclosure is not limited to a specific regiochemistry. - As set forth in
Scheme 6, treatment of a norbornane-functionalized backbone (16) can be crosslinked with a dithiol (17) in the presence of ultraviolet light to form a crosslinked particle (18). In some embodiments, a photoinitiator can be added. The thiol group can react with the olefin of the norbornyl group to form sulfur-carbon bonds (e.g., by radical addition). As set forth above inScheme 6, the regiochemistry of thiol addition can vary. The flexibility in regiochemical crosslinking is also shown in Formula VI. One of skill in the art will understand that Formula VI shows that the norbornyl group can be connected to the polymer backbone and crosslinked via a dithiol with a variety of different crosslinking regiochemistries, and the present disclosure is not limited to a specific regiochemistry. - One of skill in the art will understand that the above schemes are illustrative of the present invention and are not to be construed as limiting. For example, one of skill in the art will readily understand that any of the functional groups described above (e.g., norbornene groups, trans-cyclooctene groups, tetrazine groups) can be substituted without deviating from the spirit of the present disclosure. For example, any of the functional groups set forth above can have, for example, a methyl substituent.
- One of skill in the art will understand that it is possible to switch the nature of the functional groups and crosslinkers disclosed herein to achieve similar results as disclosed herein. That is, one of skill in the art will understand that it is possible, for example, to employ functional groups disposed along the polyester backbone to crosslink with diolefins (e.g., 1,5-hexadiene) and achieve similar results.
- In some embodiments, crosslinkers can have two functional groups (i.e., the crosslinkers can be linear and have a functional group at each end). Examples of such bifunctional crosslinkers are 1,6-hexanedithiol. In some embodiments, crosslinkers can be multifunctional (e.g., can have more than two functional groups). For example, a tetrafunctional crosslinker can have the structure of 4,4-bis(3-aminopropyl)heptane-1,7-diamine:
- One of skill in the art will understand that such a tetrafunctional crosslinker can be used, for instance, in the presence of epoxy-functionalized polymer backbones. Additionally, one of skill in the art will understand that the amine functionalities can be replaced with thiol groups to enable a tetrafunctional crosslinker in a thiol-ene reaction.
- Additionally, one of skill in the art will understand that it is possible to use other chemical reactions (e.g., robust chemical reactions such as “click” reactions) to form crosslinks as described herein.
- As used herein, crosslinkers of the present disclosure can comprise polymer (e.g., polyester, polycarbonate backbones). In other words, the crosslinker can comprise a polymer with functional groups disposed thereon that are capable of reacting with the functional groups of another polymer. For example, a polyester backbone comprising a plurality of allyl groups disposed thereon can be crosslinked by a polyester polymer comprising a plurality of free thiol groups disposed thereon. In some embodiments, the crosslinking polymer can comprise a plurality of monomer units (e.g., 100 or more, 200 or more, 300 or more, or 1000 or more monomer units). In some embodiments, the monomer units can be functionalized or unfunctionalized valerolactone units.
- The present disclosure provides for the preparation of particles of controllable size. In some embodiments, the particles can be microparticles or nanoparticles. For example, the particles described herein can have diameters between about 1 and 999 μm, including all ranges and subranges therebetween (e.g., between about 5 and about 500 μm; or about 10 μm; about 20 μm; about 50 μm; about 100 μm; or about 200 μm).
- Size optimization or size control can be accomplished by a number of different methods described herein. For example, in some embodiments, the polymers and crosslinkers described herein can be dissolved in a non-aqueous (e.g., organic) solvent. The mixture of the polymers and crosslinkers (and, optionally, initiators or catalysts) can be emulsified with an aqueous phase (e.g., water optionally comprising an emulsifying agent such as polyvinylalcohol, PVA, or PEG). The emulsion parameters can be used to control the resulting particle size. That is, in some embodiments, the particle precursors (e.g., polymers, crosslinking agents and initiators) can be dissolved within droplets of the non-aqueous solvent of the emulsion. The crosslinking reaction can then take place while the particle precursors are dissolved in the non-aqueous solvent of the emulsion. In other words, the emulsion (i.e., the non-aqueous phase), can act as a mold or cast to allow uniformly dispersed microparticles. In some embodiments, the crosslinking can take place within the emulsion (i.e., the non-aqueous phase). For example, an emulsion comprising non-aqueous droplets with the particular precursors (e.g., polyester backbone and crosslinker) dissolved therein can be irradiated. In some embodiments, all of the components of the reaction are water-insoluble and therefore dissolve in the non-aqueous droplets of the emulsion.
- Accordingly, in some embodiments, the size of the microparticles is a function of the size of the droplets (e.g., microdroplets) of the non-aqueous solvent. Thus, in some embodiments, the speed of stirring or agitation of the emulsion can be used to control the size of the non-aqueous droplets and thus the size of the resulting microparticles. In some embodiments, sonication (e.g., by probe tip or horn) can be used to control the size of the non-aqueous droplets and thus the size of the resulting microparticles.
- Thus, in some embodiments, polymer precursors (e.g., PCL) can be added at high concentrations (e.g., greater than 50 mg/mL). In some embodiments, the speed of the emulsion process can be adjusted between about 10,000 rpm and 22,000 rpm. For example, the speed of the emulsion process can be about 10,000 rpm, about 11,000 rpm, about 12,000 rpm, about 13,000 rpm, about 14,000 rpm, about 15,000 rpm, about 16,000 rpm, about 17,000 rpm, about 18,000 rpm, about 19,000 rpm, about 20,000 rpm, about 21,000 rpm, or about 22,000 rpm. In some embodiments, the percentage of surfactant (e.g., polyvinyl alcohol, polyvinylpyrollidone or polyethylene glycol) in the aqueous phase can also be used to control the droplet size (and thus the size of the resulting particles). For example, the viscosity of the aqueous phase can be controlled by the amount of polyvinyl alcohol. In some embodiments, the percentage of polyvinyl alcohol can be between about 5% (wt) and about 20% (wt). For example, the percentage of polyvinyl alcohol can be about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% by weight. Similarly, in some embodiments the molecular weight of the surfactant (e.g., polyvinyl alcohol, polyvinylpyrollidone or polyethylene glycol) can be used to control the droplet size (and thus the size of the resulting particles).
- The ratio of aqueous solvent to non-aqueous solvent can also be used to control the size of the particles. For example, in some embodiments, between about 1 and 100 mL of aqueous solvent is used (e.g., about 1, about 5, about 10, or about 15 mL of aqueous solvent). In some embodiments, between about 1 and about 10 mL of non-aqueous solvent is used (e.g., about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9 or about 10 mL of non-aqueous solvent is used). In some embodiments, the ratio of aqueous to non-aqueous solvent is between about 1:1 to about 10:1.
- After crosslinking the particles in the non-aqueous phase, the solvent (e.g., the non-aqueous solvent, the aqueous solvent, or both) can be removed. In some embodiments, removal of the solvent includes exposing the emulsion to a gas stream (e.g., an N2 stream). The gas stream can last for a number of hours (e.g., about 1 hour, about 3 hours, about 6 hours, about 12 hours, or about 24 hours).
- In another embodiment, the microparticles and macroparticles of the present disclosure can be controlled by photolithography. As set forth in Example 12, templates were formed by creating pegs of uniform size and shape which were used to create wells that are likewise of uniform size and shape. Polyesters and crosslinkers were dissolved in the wells and crosslinked to created microparticles and macroparticles of uniform size. The resulting particles can then be removed from the wells and used. In some embodiments, the molded solution can also contain a filler (e.g., a plasticizer). In some embodiments, the filler can be used to control the porosity of the resulting particles.
- In another embodiment, the size of the particles (e.g., microparticles or nanoparticles) can be controlled by milling of a corresponding macroparticle. For example, in some embodiments, the crosslinking reactions of the present disclosure can be performed in a single phase (i.e., not an emulsion) to create a macroscopic particle (e.g, a particle with a mass of >10 mg). The resulting macroparticle can then be milled (e.g., crushed) to create a plurality of nanoparticles or microparticles.
- In some embodiments, particles of the present disclosure can comprise PEG polymers attached to the polyester particle backbone. In some embodiments, the PEG polymers can be attached such that they are disposed toward the outside of the particle. For example, the PEG polymers can be attached at the terminal portion of the polyester particle backbones.
- In some embodiments, attachment of PEG polymers can help to reduce aggregation of the particles of the present disclosure. In some embodiments, other polymers such as polyvinylpyrrolidone or pluronics can be used in place of PEG to help prevent aggregation. Also, attachment of PEG polymers can make the particles more hydrophilic and help facilitate drug loading. For example, a PVL-co-PAVL microparticle was prepared according to the methods disclosed herein. Without wishing to be bound by theory, the resulting particles were hydrophobic and demonstrated some aggregation. In some embodiments, it could be difficult to load drugs into the resulting particles because the particles were non-porous and hydrophobic.
- In some embodiments, attachment of PEG polymers can be accomplished by using a hydroxy-PEG molecule as an initiator for a polymerization reaction (e.g., as an initiator for polyester formation). For example, a multi-arm PEG such as a PEG dendrimer or a six-arm, hydroxy terminated PEG can be used as a polymerization initiator.
- In contrast, preparation of particles comprising mPEG-2K-PVL-co-PAVL (i.e., particles wherein PEG was disposed on the outside of the particle) demonstrated greater hydrophilicity, less aggregation, and easier drug loading. In some embodiments, at least about 2.5% PEG can be used (e.g., as a co-solvent) to reduce aggregation of drug particles (e.g., at least about 2.5%, at least about 5%, or at least about 10%). For example,
FIG. 18A shows curcumin-loaded particles dissolved in water containing 1% tween after being dried in THF with 25% PEG as a co-solvent. Also,FIG. 18B shows a close-up view of curcumin-loaded particles dissolved in water containing 1% tween after being dried in THF with 25% PEG as a co-solvent. Without wishing to be bound by theory, the results suggest that dissolving in water comprising a surfactant can help reduce clumping of the particles. - In some embodiments, drugs can be loaded into the particles of the present disclosure by soaking the particles in a solvent (e.g., water, tetrahydrofuran (THF) or dimethylsulfoxide (DMSO)) that contains the drug. In some embodiments, the drug can be a small molecule, including, but not limited to, triamcinolone, triamcinolone hexacetonide, paclitaxel. Other drugs include, but are not limited to, bimatoprost, travaprost, brimonidine, camptothecin, tamoxifen, quercetin, thiostrepton, temozolamide, trametinib, seliciclib, fN′LFN′ YK, GCGGGDHGVSSGV, hepatocyte growth factor (HGF), and bone morphogenetic protein 2 (BMP2).
- In some embodiments, the drugs released from particles of the present disclosure can be hydrophobic. In some embodiments, particle loading with such hydrophobic drugs and subsequent release from the particles can facilitate the administration of such hydrophobic drugs (e.g., in vivo).
FIG. 13 gives loading capacities of macroparticles of the present disclosure for the drugs curcumin (as a visible surrogate for a drug), paclitaxel, triamcinolone acetonide, and triamcinolone hexacetonide. - In some embodiments, the particles (e.g., microparticles such as 10 μm microparticles) can provide sustained release (e.g., about 3 months of sustained release of a drug (e.g., triamcinolone hexacetonide) in a relevant animal model.
-
FIG. 4 shows a schematic of the method for loading drugs into particles of the present disclosure. As set forth inFIG. 4 , particles are suspended in an organic solvent containing a drug. The resulting mixture is stirred, and the drug can incorporate into the porous regions of the particles. After purification, the drugs can be lyophilized and stored until use. - In some embodiments, the loading procedure can affect the amount of drug that is absorbed into a particle of the present disclosure. For example, as set forth in Examples 7 and 8, 25 mg of 75:25 (mPEG-PVL-PAVL:PVL-PAVL) particles were swollen overnight with 2 mg/mL triamcinolone hexacetonide in THF. However, without wishing to be bound by theory, slow addition of greater volumes of water can facilitate greater uptake of triamcinolone hexacetonide by allowing the drug to preferentially partition into the particles. As set forth in Examples 7 and 8, slow addition of water enabled 67% loading efficiency. Additional parameters, in addition to the rate of water addition, that can affect the loading of a drug into a particle of the present disclosure are, for instance, the solvent in which the drug is dissolved, the time that the particles soak with the drug, and the volume of water used. Other parameters include the pH and the ionic strength of the solvent. For example, protic organic solvents such as methanol or ethanol can be used in place of water to facilitate loading of drug into a particle of the present disclosure.
- Without wishing to be bound by theory, soaking the particles of the present disclosure, (e.g., in THF, in the presence of a drug) can cause the particles to swell. For example, Example 5 shows that particles of the present disclosure can change in size (e.g., can swell) depending on the solvent in which they are placed.
FIG. 5 shows a histogram of crosslinked mPEG-b-(PVL-coPAVL) microparticles demonstrating that had an average diameter of about 79 nm when placed in water. In some embodiments, the same particles swelled to a diameter of about 85 nm when soaked in dimethylsulfoxide (DMSO) as set forth inFIG. 6 . The particles swelled to a diameter of about 208 nm when soaked in THF, as set forth inFIG. 7 . In some embodiments, the difference in volume of a particle can range by a factor of 5-20. For example, a particle soaked in THF can be about 2× as large, about 3× as large, about 4× as large, about 5× as large, about 6× as large, about 7× as large, about 8× as large, about 9× as large, about 10× as large, about 11× as large, about 12× as large, about 13× as large, about 14× as large, about 15× as large, about 16× as large, about 17× as large, about 18× as large, about 19× as large, or about 20× as large, as a particle soaked in water. For comparison,FIG. 8 sets forth a histogram of non-crosslinked mPEG-b-PVL-co-PAVL microparticles after soaking in water. - Additionally,
FIG. 9 sets forth the swelling of particles that have been suspended in THF.FIG. 9A shows a histogram and an image of microparticles after crosslinking. andFIG. 9B andFIG. 9C show histograms and images of microparticles after a DMSO washing step and an ethanol washing step, respectively.FIG. 9D shows images and a histogram of particles soaked in THF. As set forth inFIG. 9D , the THF-soaked particles can be larger than the particles soaked in other solvents such as water or ethanol. - The release of drugs from particles of the present disclosure can be dependent upon the crosslinking density of the particles. For example, high crosslinking density can lead to slower drug release as high crosslinking density can lead to slower hydrolysis and thus slower degradation of the particles.
- The release of drugs from particles of the present disclosure can be dependent upon the density of the particles. For instance, in some embodiments increasing the length of the crosslinker can decrease the density of the particle and allow for faster release of drug from a given particle.
- In some embodiments, the particles disclosed herein display low crystallinity. Without wishing to be bound by theory, the low crystallinity can be advantageous for diffusion-mediated release.
FIGS. 28 and 29 shows that microparticles of the present disclosure have low crystallinity at high crosslinking density. - The disclosure is further illustrated by the following examples and synthesis examples, which are not to be construed as limiting this disclosure in scope or spirit to the specific procedures herein described. It is to be understood that the examples are provided to illustrate certain embodiments and that no limitation to the scope of the disclosure is intended thereby. It is to be further understood that resort may be had to various other embodiments, modifications, and equivalents thereof which may suggest themselves to those skilled in the art without departing from the spirit of the present disclosure and/or scope of the appended claims.
- Unless otherwise indicated, quantitation of drug products was carried out using HPLC methods. Calibration curves for drugs used herein (e.g., triamcinolone, triamcinolone hexacetonide, triamcinolone acetonide, paclitaxel, and curcumin) were prepared by injecting known concentrations of the drugs and measuring the area under the curve at each concentration. Analyses were carried out using an Agilent Zorbax Eclipse XDB-C18 column (150×4.6 mm i.d.) with a 12.5×4.6 mm guard column. The parameters for each drug are given below in Table
-
TABLE 1 Calibration Parameters for Drug Concentrations Injection Retention Flow Detection Mobile Drug Volume time Rate wavelength Phase Cal. Slope R2 Triamcinolone 20 μL 3 min 1.2 mL/min 240 nm MeOH:H2O Y = 57.882x 0.9999 hexacetonide 90:10 Paclitaxel 20 μL 7.8 min 1 mL/min 227 nm MeOH:H2O Y = 73.156x 0.9998 50:50 Curcumin 20 μL 4.45 min 1 mL/min 420 nm ACN:H2O: Y = 338.71x 0.9996 AcOH 55:45:0.1 - Benzyl alcohol (60 μl), valerolactone (8 mL) and allylvalerolactone (2 mL) were dissolved in toluene (20 mL) and triazabicyclodecene (catalyst) was added 2% mol:monomer and stirred at room temperature for 4 hours.
FIG. 10 shows a 1HNMR spectrum of PVL-co-PAVL polymer with a molecular weight of 17200 g/mol (i.e., about 128 units of valerolactone and about 14 units of allylvalerolactone). The number average molecular weight of the polymer was about 12,200 g/mol, with a peak molecular weight of about 14100 g/mol. The polydispersity index was bout 1.41. The melting temperature was about 35° C. The temperature of recovery was about 11° C.FIG. 10B shows a gel permeation chromatography plot of the PVL-co-PAVL nanoparticles. - The mixture was subjected to gel permeation chromatography. The weight average molecular weight was about 17,200 g/mol.
- Allyl lactide is prepared according the method disclosed in U.S. Pat. No. 8,758,828 to Markland, et. al. Benzyl alcohol, valerolactone and allyl lactide are dissolved in triazabicyclodecene and stirred at room temperature for 4 hours. The resulting polymer is isolated and used for crosslinking microparticles.
- Polycaprolactone homopolymer (PCL; 50 mg; 50 kDa; 1 mmol), polyvalerolactone (PVL; 50 mg) and polyallylvalerolactone (PAVL; 50 mg (6700 g/mol; 19% allylvalerolactone and 81% valerolactone)) and hexanedithiol (1 —SH group per alkene) were dissolved in 1 mL dichloromethane. 2,2-Dimethoxy-2-phenylacetophenone (DMPA; 3.4 mg; 0.2 equivalents per alkene) was added and the solution was added dropwise to 20 mL of water containing 5% polyvinyl alcohol. The mixture was homogenized with stirring (i.e., a Polytron® mechanical homogenizer at 22,000 rpm) for five minutes. The homogenized mixture was irradiated at 365 nm-4 mW under stirring for 30 minutes.
- The mixture was stirred for 3 hours to allow the dichloromethane to evaporate. The mixture was then centrifuged at 4000 rpm at 10° C. for 10 minutes. The aqueous solution containing polyvinyl alcohol was poured off and the particles were rinsed with distilled water. The particles were then centrifuged and rinsed with water as above an additional three times.
- The particles were then dispersed in DMSO and centrifuged at 4000 rpm at 20° C. for ten minutes. The DMSO was poured off and the process was repeated another two times. The resulting crosslinked particles were swollen and semi-transparent and did not dissolve in DMSO.
-
FIG. 1A shows a photo of a PCL-co-PAVL copolymer at a scale of about 1500 μm produced by the above-method.FIGS. 1B, 1C, and 1D show photos of a PCL-co-PAVL/PVL copolymer produced by the above-method at a scale of 400 μm, 600 μm, and 20 μm, respectively. The particles comprised between 0.01% and 20% polyallylvalerolactone (PAVL), with the remainder comprising polycaprolactone (PCL) and polyvalerolactone (PVL). - Polycaprolactone homopolymer (PCL; 50 mg; 50 kDa; 1 mmol) and polyallylvalerolactone (PVL-co-PAVL; 50 mg) were dissolved in 1 mL dichloromethane. The solution was added dropwise to 20 mL of water containing 5% polyvinyl alcohol. The mixture was homogenized with stirring (i.e., a Polytron® mechanical homogenizer at 22,000 rpm) for five minutes. The homogenized mixture was irradiated at 365 nm-4 mW under stirring for 30 minutes. No crosslinker or DMPA was added.
- The mixture was stirred for 3 hours to allow the dichloromethane to evaporate. The mixture was then centrifuged at 4000 rpm at 10° C. for 10 minutes. The aqueous solution containing polyvinyl alcohol was poured off and the particles were rinsed with distilled water. The particles were then centrifuged and rinsed with water as above an additional three times.
- The mixture was then dispersed in DMSO and centrifuged at 4000 rpm at 20° C. for ten minutes. The DMSO was poured off and the process was repeated another two times. Although particles were formed, the particle precursors dissolved in DMSO and were not recovered. This example was performed as a control experiment and the results demonstrate that crosslinking is necessary to produce microparticles of the present disclosure.
- Polyallylvalerolactone (PAVL; 100 mg (6700 g/mol; 19% allylvalerolactone and 81% valerolactone)) and hexanedithiol (1 —SH group per alkene) were dissolved in 1 mL dichloromethane. 2,2-Dimethoxy-2-phenylacetophenone (DMPA; 0.2 equivalents per alkene) was added and the solution was added dropwise to 20 mL of water containing 5% polyvinyl alcohol. The mixture was homogenized with stirring (i.e., a Polytron® mechanical homogenizer at 22,000 rpm) for five minutes. The homogenized mixture was irradiated at 365 nm-4 mW under stirring for 30 minutes.
- The mixture was stirred for 3 hours to allow the dichloromethane to evaporate. The mixture was then centrifuged at 4000 rpm at 10° C. for 10 minutes. The aqueous solution containing polyvinyl alcohol was poured off and the particles were rinsed with distilled water. The particles were then centrifuged and rinsed with water as above an additional three times.
- The particles were then dispersed in DMSO and centrifuged at 4000 rpm at 20° C. for ten minutes. The DMSO was poured off and the process was repeated another two times. The resulting crosslinked particles were swollen and semi-transparent and did not dissolve in DMSO.
-
FIG. 2A shows a photo of a PVL-co-PAVL copolymer at a scale of about 1500 μm produced by the above-method.FIGS. 2B, 2C, and 2D show photos of a PVL-co-PAVL copolymer produced by the above-method at a scale of 400 μm, 600 μm, and 20 μm, respectively. - Polyallylvalerolactone (PAVL; 100 mg) was dissolved in 1 mL dichloromethane. The solution was added dropwise to 20 mL of water containing 5% polyvinyl alcohol. The mixture was homogenized with stirring (i.e., a Polytron® mechanical homogenizer at 22,000 rpm) for five minutes. No DMPA or crosslinker was added. The homogenized mixture was irradiated at 365 nm-4 mW under stirring for 30 minutes.
- The mixture was stirred for 3 hours to allow the dichloromethane to evaporate. The mixture was then centrifuged at 4000 rpm at 10° C. for 10 minutes. The aqueous solution containing polyvinyl alcohol was poured off and the particles were rinsed with distilled water. The particles were then centrifuged and rinsed with water as above an additional three times.
- The mixture was then dispersed in DMSO and centrifuged at 4000 rpm at 20° C. for ten minutes. The DMSO was poured off and the process was repeated another two times. Although particles were formed, the particle precursors dissolved in DMSO and were not recovered. This example was performed as a control experiment and the results demonstrate that crosslinking is necessary to produce microparticles of the present disclosure.
- 50 mg of mPEG-PVL-PAVL (6.0×10−5 mol allyl), 5 mg DMPA (0.25 eq/allyl) and 4.4 μL 1,6-hexanedithiol (0.5 eq/allyl) were dissolved in 3 mL THF. The polymer solution in THF was added dropwise with stirring to 10 mL deionized water in a 20-mL glass vial. The solvent was evaporated for about 18 hours and then the solution was irradiated with UV light (365 nm) for five minutes. The resulting microparticles were characterized via dynamic light scattering (DLS).
-
FIG. 5 shows a DLS plot of the crosslinked particles in water. As shown, the particles are about 100 nm in diameter. Table 2 below shows the results of the DLS analysis. -
TABLE 2 DLS Analysis of Crosslinked mPEG-b-(PVL-coPAVL) Microparticles in Water Cumulant Results Distribution Results Z-average Size (d) (nm) 78.65 (nm) % Int σ Pd index 0.140 Peak 1 90.69 97.9 30.10 Poly dispersity 29.4 Peak 2 26.81 2.1 4.420 (nm) % 37.4 Peak 3 0.000 0.0 0.000 Polydispersity Derived kcps 48,863.4 -
FIG. 6 shows a DLS plot of the crosslinked particles in DMSO. As shown, the particles are about 100 nm in diameter. Table 3 below shows the results of the DLS analysis. -
TABLE 3 DLS Analysis of Crosslinked mPEG-b-(PVL-coPAVL) Microparticles in DMSO Cumulant Results Distribution Results Z-average Size (d) (nm) 85.22 (nm) % Int σ Pd index 0.077 Peak 1 91.61 100.0 24.28 Poly dispersity 23.6 Peak 2 0.000 0.0 0.000 (nm) % 27.7 Peak 3 0.000 0.0 0.000 Poly dispersity Derived kcps 3,424.2 -
FIG. 7 shows a DLS plot of the crosslinked particles in THF. As shown, the particles are between about 100 nm and 1000 nm in diameter. Table 4 below shows the results of the DLS analysis. -
TABLE 4 DLS Analysis of Crosslinked mPEG-b-(PVL-coPAVL) Microparticles in THF Distribution Results Cumulant Results Size (d) Z-average (nm) 208.4 (nm) % Int σ % Pd Pd index 0.171 Peak 1 236.4 100.0 84.76 35.9 Polydispersity (nm) 86.1 Peak 20.000 0.0 0.000 0 % Polydispersity 41.3 Peak 3 0.000 0.0 0.000 0 Derived kcps 19181.1 -
FIG. 11A shows a microscope image of mPEG-b-PAVL-co-PVL macroparticles (80:20) produced by this method at a resolution of about 1 mm. -
FIG. 11B shows a microscope image of mPEG-b-PAVL-co-PVL macroparticles (80:20) produced by this method at a resolution of about 200 μm. -
FIG. 11C shows a first microscope image of mPEG-b-PAVL-co-PVL macroparticles (80:20) produced by this method at a resolution of about 10 μm. -
FIG. 11D shows a second microscope image of mPEG-b-PAVL-co-PVL macroparticles (80:20) produced by this method at a resolution of about 10 μm. - 50 mg of mPEG-PVL-PAVL (6.0×10−5 mol allyl) and 4.4 μL 1,6-hexanedithiol (0.5 eq/allyl) were dissolved in 3 mL THF. The polymer solution in THF was added dropwise with stirring to 10 mL deionized water in a 20-mL glass vial. No photoinitiator was added, and the emulsion was irradiated with UV light (365 nm) for five minutes as a control measure. The solvent was evaporated for about 18 hours, and the resulting micelles were characterized via dynamic light scattering.
-
FIG. 8 shows a DLS image of non-crosslinked microparticles produced as in the method above in water, andFIG. 12 shows a DLS plot of non-crosslinked particles in water. As shown, the particles are about 100 nm in diameter. Table 5 below shows the results of the DLS analysis. Without wishing to be bound by theory, because the particles were not crosslinked, they re-dissolved in organic solvent. -
TABLE 5 DLS Analysis of Crosslinked mPEG-b-(PVL-coPAVL) Microparticles in Water Cumulant Results Distribution Results Z-average Size (d) (nm) 80.89 (nm) % Int σ Pd index 0.173 Peak 1 94.69 100.0 32.66 Poly dispersity 33.6 Peak 2 0.000 0.0 0.000 (nm) % 41.6 Peak 3 0.000 0.0 0.000 Poly dispersity Derived kcps 44486.7 - 25 mg of 75:25 (mPEG-PVL-PAVL:PVL-PAVL) particles were swollen overnight with 2 mg/mL triamcinolone hexacetonide in THF. 10 mL water including 0.1% tween was then added dropwise. The resulting mixture was centrifuged, the supernatant was collected, and the addition of 10 mL water including 0.1% tween was added dropwise again (2×; 30 mL total).
- After the first centrifugation, it was observed that the particles did not easily resuspended in 10 mL water containing 0.1% tween. Without wishing to be bound by theory, this may be due to the fact that the triamcinolone hexacetonide crystallized on the surface of the particles. Without wishing to be bound by theory, this may be due to the relatively fast addition of water and the limited solubility of triamcinolone hexacetonide, which caused it to crystallize. Also without wishing to be bound by theory, the release profile showed relatively rapid release from the particles, likely a result of the surface-crystallized drug re-dissolving in solution.
- 15-mg macroparticles were placed in 0.5 mL of THF containing 15 mg of drug. After 2 hours of swelling, the cylinders were washed with fresh THF and dried at room temperature for 24 hours.
- 40 mg of microparticles were swollen in 0.5 mL of tetrahydrofuran containing 10 mg of drug. Slow addition of water was used in some embodiments for the addition to microparticles.
- The loading efficiency, which included surface-bound drug or free drug in solution, was 67%. Upon suspending the particles in dissolution media, 20% of the triamcinolone hexacetonide was released within an hour, and 30% was released within 2 hours.
- Without wishing to be bound by theory, very slow addition of larger volumes of water can give triamcinolone hexacetonide the opportunity to preferentially partition into the macroparticles. Accordingly,
FIG. 13 shows the loading capacity of the 15-mg macroparticles of the present disclosure with curcumin (CCM), triamcinolone hexacetonide (TAH), triamcinolone acetonide (TAA), and paclitaxel (PTX). -
FIG. 14 shows differential scanning calorimetry plots of macroparticles loaded with curcumin (CCM), triamcinolone hexacetonide (TAH), triamcinolone acetonide (TAA), and paclitaxel (PTX) and without drugs.FIG. 15 shows FTIR spectra of microparticles loaded with curcumin (CCM), triamcinolone hexacetonide (TAH), triamcinolone acetonide (TAA), and paclitaxel (PTX) and without drugs. - Crosslinked microparticles (15 mg) were loaded with 2.5 mg curcumin by overnight soaking in THF followed by the slow addition of 50 mL PBS containing 0.1% Tween. The microparticles were rinsed with THF to remove free curcumin and dried overnight.
- It was observed that microparticles thus produced formed “flakes” that could not be re-suspended in THF or PBS buffer solution upon drying. Microscope images of the flakes are shown in
FIG. 16 after being dried overnight, andFIG. 17 shows a release profile of curcumin from microscopic flakes. The flakes could not be re-suspended in PBS buffer. - The release profile of curcumin of microparticle flakes produced by the method described above. The release profile is further quantified in Table 6, below.
-
TABLE 6 Release Profile of Microparticle Flakes Conc Final Conc AUC (μg/mL) Dilution (mg/mL) Efficiency % Loading Initial Release 489.8 1.259093597 251.8187193 0.251818719 1.134190112 1.937067072 Total (μg % retention curcumin) in flakes Extraction 2782 7.151487108 143.0297422 143.0297422 56.79869334 After 48 H - As shown in Table 6 above, 51% of curcumin was released after 48 hours, and 57% was recovered in post-release extraction of the flakes.
- In order to address the difficulties re-suspending the microparticle flakes, particles were dried with 25% PEG400 as a co-solvent. Particles dried in PEG, included those that had been loaded with curcumin, could be re-suspended in water with Tween or THF.
FIGS. 18A and 18B show microscope images of microparticles of the invention after being dried with 25% PEG400 as a co-solvent.FIG. 19A shows a microscope image of microparticle flakes in water after drying with 2.5% PEG400 as a co-solvent.FIG. 19B shows a microscope image of microparticle flakes in THF after drying with 2.5% PEG400 as a co-solvent.FIG. 19C shows a microscope image of microparticle flakes in water after drying with 5% PEG400 as a co-solvent.FIG. 19D shows a microscope image of microparticle flakes in THF after drying with 5% PEG400 as a co-solvent.FIGS. 18 and 19 demonstrate that as little as 2.5% PEG400 was capable of re-suspending microparticle flakes. -
FIG. 9A shows a histogram and a optical microscope image of 25% PVL-co-PAVL microparticles after crosslinking. The average diameter was 6.8 μm±2.5 nm.FIG. 9B shows a histogram and OM image of the same microparticles after a DMSO washing step (average diameter 6.4 μm±1.8 nm) andFIG. 9C shows a histogram and OM image of the particles after an ethanol washing step (average diameter 8 μm±2.5 nm).FIG. 9D shows a histogram and OM image of the particles after swelling in THF, after which the average diameter was 11.1 μm±4.5 nm. The results show that in some embodiments, suspending the particles in THF causes the particles to swell. - Triamcinolone acetonide, triamcinolone hexacetonide, and paclitaxel were dissolved in water with varying concentrations of surfactants as co-solvents. Sodium dodecyl sulfate (SDS) is an anionic surfactant with a critical micelle concentration (CDC) of 8.2 mM. The hydrophobic lipophilic balance (HLB) is 40.
Tween 80 is a non-ionic surfactant with a critical micelle concentration (CMC) of 0.012 mM, and a hydrophobic lipophilic balance (HLB) of 15. -
FIG. 20 shows that certain drugs can by hydrophobic, and can require addition of surfactants (e.g. sodium dodecyl sulfate and Tween 80) to dissolve in water.FIG. 20A shows an aqueous solubility plot of triamcinolone acetonide in the presence ofsurfactants Tween 80 and SDS.FIG. 20B shows an aqueous solubility plot of triamcinolone hexacetonide in the presence ofsurfactants Tween 80 and SDS.FIG. 20C shows an aqueous solubility plot of paclitaxel in the presence ofsurfactants Tween 80 and SDS. - A crosslinked macroparticle weighing about 15 mg comprising PVL-co-PAVL (MW=14760 g/mol, 13% AVL, 87% VL) was loaded with 2.5 mg paclitaxel by overnight soaking in THF followed by the slow addition of 50 mL PBS containing 0.1% Tween.
- The macroparticles were suspended in PBS (0.1% Tween) and the release rate was observed. The macroparticles released 5% of the paclitaxel after 3 hours at room temperature and about 5% after 24 hours at room temperature. The loading capacity was found to be 1.7% w/w, and the loading efficiency was 30%.
- A second cylinder (was loaded with curcumin and dissolved in THF. The amount of drug in the cylinder was 1.176 mg (9.64% capacity). A release profile is shown in
FIG. 21 .FIG. 21 shows that almost all of the curcumin is released after about eight days. Without wishing to be bound by theory, it is proposed that mechanical agitation (e.g., stirring with a stir bar) can affect the release parameters of particles of the present disclosure, causing faster release. -
FIG. 22 shows a 20-day curcumin release profile from a 13-mg and 12-mg macroparticle. - Two cylinders (were loaded with triamcinolone hexacetonide and dissolved in THF. The amount of drug in the first cylinder (labelled with a circle) was 1.118 mg (9.12% capacity), and the amount of drug in the second cylinder (labelled with an “X”) was 0.901 (11.651% capacity). A release profile of both cylinders is shown in
FIG. 23 .FIG. 23 shows that the release profile for both cylinders is very similar, and that about 60% of total drug is released after about 6 days. -
FIG. 24 shows a 20-day triamcinolone hexacetonide release profile from a 13.3-mg and 9.2-mg macroparticle. -
FIG. 25 shows a comparison of the release profiles of curcumin, triamcinolone hexacetonide (TAH), triamcinolone acetonide (TAA), and paclitaxel (PTX). - Microparticles were fabricated with a silicon master template with 10 μm cylindrical pegs which serve as the inverse for a degradable gelatin template (i.e., the pegs can control the size of the wells. Wells on a gelatin template were filled with polymer solution, crosslinked, and harvested. The resulting particles had a homogenous size distribution.
FIG. 26 shows an example micrograph of the photolithography template (G. Acharyo; Journal ofControlled Release 141; 2010; pp. 314-319). - 5 mL of warm 30% (w/v) gelatin solution was poured over a pegged silicon template. The solution and template were cooled in a refrigerator for five minutes. The template was peeled away from the gelatin mold to produce a gelatin mold with individual wells.
- 100 μL of 20% PAVL-PVL in dichloromethane was spread on the template along with 1,6-hexanedithiol and 20% DPMA (per allyl group). The template and polymer mixture was covered with a glass slide and irradiated with UV light (365 nm) for ten minutes over ice. The glass slide was removed and the solvent was evaporated. The template was dissolved in water and the microparticles were collected by centrifugation.
-
FIG. 27A shows a gelatin template with pegs under a microscope.FIGS. 27B and 27C show microscope images of microparticles prepared by the above-method. - Particles of the present disclosure were evaluated using differential scanning calorimetry (DSC). The particles comprised PVL-co-PAVL (MW=6700 g/mol, 19% AVL, 81% VL).
FIG. 28 shows DSC plots of microparticles with different degrees of crosslinking. The DSC plots measured the enthalpy of melting (Δ°Hm) of particles freeze dried for four days.FIG. 28A shows a DSC plot of a control microparticle with no crosslinking and shows relatively high crystallinity.FIG. 28B shows a DSC plot of a microparticle with 50% crosslinking. The DSC plot shows relatively low crystallinity.FIG. 28C shows a DSC plot of a microparticle with 100% crosslinking. The DSC plot shows even lower crystallinity than the 50% crosslinked particles. - Similarly,
FIG. 29 shows DSC plots of microparticles with different degrees of crosslinking. The DSC plots measured the enthalpy of melting (Δ°Hm) of particles freeze dried for four days.FIG. 29A shows a DSC plot of a control microparticle with no crosslinking (i.e., just the polymer backbone is analyzed).FIG. 29B shows a DSC plot of a microparticle with 50% crosslinking. The DSC plot shows low crystallinity.FIG. 29C shows a DSC plot with 100% crosslinking. The DSC plot shows low crystallinity. Without wishing to be bound by theory, the low crystallinity of the drug can help facilitate diffusion-mediated release. - The middle trace shows a trace of 10% PAVL microparticles. The number average molecular weight (Mn) was 12,000 and the weight average molecular weight (Mw) was 17,500. The polydispersity index (PDI) was 1.45. The particles were found to be semi-crystalline and the melting temperature was found to be between about 25-35° C.
- The top trace shows a trace of 8% PAVL microparticles. The number average molecular weight (Mn) was 32,700 and the weight average molecular weight (Mw) was 50,000. The polydispersity index (PDI) was 1.55. The particles were found to be an amorphous rubber.
- Nude mice were implanted in hind limb with GL261 glioma cells and were treated with fluorescently labeled GIRLRG peptide and daily radiation of 3 Gy for 3 days. Mice were similarly treated with systemic taxol, taxol-loaded, control peptide particles, taxol-loaded targeted microparticles, and naked particles.
- Polyvalerolactone (PVL; 50 mg) and poly(trans-cyclooctene)valerolactone (PtCOVL; 50 mg (6700 g/mol; 19% (trans-cyclooctene)valerolactone and 81% valerolactone)) and hexanedi-tetrazine (1 tetrazine group per trans-cyclooctene) are dissolved in 1 mL dichloromethane. The solution is added dropwise to 20 mL of water containing 5% polyvinyl alcohol. The mixture is homogenized with stirring (i.e., a Polytron® mechanical homogenizer at 22,000 rpm) for five minutes. The homogenized mixture is stirred for about an additional 12-48 hours.
- The mixture is then centrifuged at 4000 rpm at 10° C. for 10 minutes. The aqueous solution containing polyvinyl alcohol is poured off and the particles are rinsed with distilled water. The particles are then centrifuged and rinsed with water as above an additional three times.
- Polyallylvalerolactone (PAVL; 100 mg (6700 g/mol; 19% allylvalerolactone and 81% valerolactone)) and hexanedithiol (1 —SH group per alkene) are dissolved in 1 mL dichloromethane. 2,2-Dimethoxy-2-phenylacetophenone (DMPA; 0.2 equivalents per alkene) is added and the solution is sprayed on to a 20 mL water bath containing 5% polyvinyl alcohol using an electrosprayer. The electrosprayed droplets and the homogenized mixture are irradiated at 365 nm-4 mW under stirring for 30 minutes.
- The mixture is stirred for 3 hours to allow the dichloromethane to evaporate. The mixture is then centrifuged at 4000 rpm at 10° C. for 10 minutes. The aqueous solution containing polyvinyl alcohol is poured off and the particles are rinsed with distilled water. The particles are then centrifuged and rinsed with water as above an additional three times.
- The particles are then dispersed in DMSO and centrifuged at 4000 rpm at 20° C. for ten minutes. The DMSO is poured off and the process is repeated another two times.
- Polyallylvalerolactone (PAVL; 100 mg (6700 g/mol; 19% allylvalerolactone and 81% valerolactone)) and hexanedithiol (1 —SH group per alkene) are dissolved in 1 mL dichloromethane. 2,2-Dimethoxy-2-phenylacetophenone (DMPA; 0.2 equivalents per alkene) is added and the solution is sprayed on to a 20 mL water bath containing 5% polyvinyl alcohol using a spray dryer. The spray-dried droplets and the homogenized mixture are irradiated at 365 nm-4 mW under stirring for 30 minutes.
- The mixture is stirred for 3 hours to allow the dichloromethane to evaporate. The mixture is then centrifuged at 4000 rpm at 10° C. for 10 minutes. The aqueous solution containing polyvinyl alcohol is poured off and the particles are rinsed with distilled water. The particles are then centrifuged and rinsed with water as above an additional three times.
- The particles are then dispersed in DMSO and centrifuged at 4000 rpm at 20° C. for ten minutes. The DMSO is poured off and the process is repeated another two times.
- While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and other variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/871,339 US20230190664A1 (en) | 2015-10-09 | 2022-07-22 | Crosslinked particles |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562239758P | 2015-10-09 | 2015-10-09 | |
US201662281631P | 2016-01-21 | 2016-01-21 | |
US201662313013P | 2016-03-24 | 2016-03-24 | |
US15/289,005 US10258578B2 (en) | 2015-10-09 | 2016-10-07 | Crosslinked particles |
US16/287,690 US11426356B2 (en) | 2015-10-09 | 2019-02-27 | Crosslinked particles |
US17/871,339 US20230190664A1 (en) | 2015-10-09 | 2022-07-22 | Crosslinked particles |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/287,690 Continuation US11426356B2 (en) | 2015-10-09 | 2019-02-27 | Crosslinked particles |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230190664A1 true US20230190664A1 (en) | 2023-06-22 |
Family
ID=58488602
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/289,005 Active US10258578B2 (en) | 2015-10-09 | 2016-10-07 | Crosslinked particles |
US16/287,690 Active US11426356B2 (en) | 2015-10-09 | 2019-02-27 | Crosslinked particles |
US17/871,339 Pending US20230190664A1 (en) | 2015-10-09 | 2022-07-22 | Crosslinked particles |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/289,005 Active US10258578B2 (en) | 2015-10-09 | 2016-10-07 | Crosslinked particles |
US16/287,690 Active US11426356B2 (en) | 2015-10-09 | 2019-02-27 | Crosslinked particles |
Country Status (8)
Country | Link |
---|---|
US (3) | US10258578B2 (en) |
EP (2) | EP4019575B1 (en) |
JP (3) | JP6852079B2 (en) |
CN (1) | CN109843996B (en) |
AU (2) | AU2016335866B2 (en) |
CA (1) | CA3001329A1 (en) |
ES (2) | ES2973475T3 (en) |
WO (1) | WO2017062871A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2973475T3 (en) | 2015-10-09 | 2024-06-20 | Le Devedec Frantz | Reticulated particles |
US11905377B2 (en) | 2019-01-17 | 2024-02-20 | Pendant Biosciences, Inc. | Factors controlling drug release in cross-linked poly(valerolactone) based matrices |
JP2023507783A (en) * | 2019-12-19 | 2023-02-27 | ペンダント バイオサイエンシズ インコーポレイテッド | Crosslinked PLA-based copolymer |
WO2023190183A1 (en) * | 2022-03-29 | 2023-10-05 | 株式会社カネカ | Crosslinked resin particles and method for producing same |
WO2023190185A1 (en) * | 2022-03-29 | 2023-10-05 | 株式会社カネカ | Thermoplastic resin composition |
WO2023190184A1 (en) * | 2022-03-29 | 2023-10-05 | 株式会社カネカ | Thermoplastic resin composition |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2476589C (en) | 2002-02-27 | 2014-02-25 | Pharmain, Ltd. | Compositions for delivery of therapeutics and other materials, and methods of making and using the same |
US6800663B2 (en) | 2002-10-18 | 2004-10-05 | Alkermes Controlled Therapeutics Inc. Ii, | Crosslinked hydrogel copolymers |
CA2654302A1 (en) | 2006-06-05 | 2007-12-13 | Massachusetts Institute Of Technology | Crosslinked, degradable polymers and uses thereof |
CN100546661C (en) * | 2006-12-01 | 2009-10-07 | 华南理工大学 | A kind of preparation method of in situ pore-forming self-setting calcium phosphate composite tissue engineering scaffold |
US20130142733A1 (en) * | 2007-11-05 | 2013-06-06 | Vanderbilt University | Multifunctional degradable nanoparticles with control over size and functionalities |
US20110274620A1 (en) | 2007-11-05 | 2011-11-10 | Harth Eva M | Multifunctional degradable nanoparticles with control over size and functionalities |
ES2744834T3 (en) * | 2007-11-05 | 2020-02-26 | Univ Vanderbilt | Multifunctional degradable nanoparticles with control over size and functionality |
JP6150522B2 (en) | 2009-12-21 | 2017-06-21 | エボニック コーポレイションEvonik Corporation | Process for preparing cyclic esters containing unsaturated functional groups and polyesters prepared therefrom |
WO2013169938A2 (en) * | 2012-05-08 | 2013-11-14 | Vanderbilt University | Polycarbonate containing compounds and methods related thereto |
ITTO20130431A1 (en) | 2013-05-28 | 2014-11-29 | Fond Istituto Italiano Di Tecnologia | COPOLYMER AND NANOPARTICLES OBTAINED FROM THEM FOR THE DRIVING OF A DRUG |
WO2016174116A1 (en) * | 2015-04-27 | 2016-11-03 | Eggplant S.R.L. | Polyester composition and method for producing the same |
ES2973475T3 (en) | 2015-10-09 | 2024-06-20 | Le Devedec Frantz | Reticulated particles |
-
2016
- 2016-10-07 ES ES21211254T patent/ES2973475T3/en active Active
- 2016-10-07 WO PCT/US2016/056135 patent/WO2017062871A1/en active Application Filing
- 2016-10-07 EP EP21211254.4A patent/EP4019575B1/en active Active
- 2016-10-07 ES ES16854494T patent/ES2906596T3/en active Active
- 2016-10-07 US US15/289,005 patent/US10258578B2/en active Active
- 2016-10-07 JP JP2018538068A patent/JP6852079B2/en active Active
- 2016-10-07 AU AU2016335866A patent/AU2016335866B2/en active Active
- 2016-10-07 CN CN201680072252.2A patent/CN109843996B/en active Active
- 2016-10-07 CA CA3001329A patent/CA3001329A1/en active Pending
- 2016-10-07 EP EP16854494.8A patent/EP3359591B1/en active Active
-
2019
- 2019-02-27 US US16/287,690 patent/US11426356B2/en active Active
-
2021
- 2021-03-10 JP JP2021037974A patent/JP7104198B2/en active Active
- 2021-05-10 AU AU2021202965A patent/AU2021202965B2/en active Active
-
2022
- 2022-07-07 JP JP2022109826A patent/JP7500659B2/en active Active
- 2022-07-22 US US17/871,339 patent/US20230190664A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN109843996B (en) | 2022-09-06 |
US20190262274A1 (en) | 2019-08-29 |
AU2021202965A1 (en) | 2021-06-03 |
JP6852079B2 (en) | 2021-03-31 |
EP4019575B1 (en) | 2023-12-06 |
JP2019500403A (en) | 2019-01-10 |
JP2022130727A (en) | 2022-09-06 |
US10258578B2 (en) | 2019-04-16 |
JP7104198B2 (en) | 2022-07-20 |
EP3359591A4 (en) | 2019-05-29 |
CN109843996A (en) | 2019-06-04 |
ES2973475T3 (en) | 2024-06-20 |
ES2906596T3 (en) | 2022-04-19 |
WO2017062871A1 (en) | 2017-04-13 |
AU2016335866B2 (en) | 2021-02-11 |
AU2021202965B2 (en) | 2023-07-20 |
US20170100343A1 (en) | 2017-04-13 |
EP3359591B1 (en) | 2021-12-01 |
CA3001329A1 (en) | 2017-04-13 |
JP2021102622A (en) | 2021-07-15 |
JP7500659B2 (en) | 2024-06-17 |
EP3359591A1 (en) | 2018-08-15 |
AU2016335866A1 (en) | 2018-05-17 |
EP4019575A1 (en) | 2022-06-29 |
US11426356B2 (en) | 2022-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230190664A1 (en) | Crosslinked particles | |
US10245244B2 (en) | Pharmaceutical formulations for the treatment of pulmonary arterial hypertension | |
Nelson et al. | Extended and sequential delivery of protein from injectable thermoresponsive hydrogels | |
US20060233857A1 (en) | Degradable elastomeric network | |
US11504340B2 (en) | Ocular compositions | |
Jiang et al. | PLGA nanoparticle platform for trans-ocular barrier to enhance drug delivery: a comparative study based on the application of oligosaccharides in the outer membrane of carriers | |
Bertram et al. | Using polymer chemistry to modulate the delivery of neurotrophic factors from degradable microspheres: delivery of BDNF | |
CN107206099A (en) | For sustained release antiglaucoma agent with the composition of control intraocular pressure | |
JP2023511978A (en) | Sustained-release matrix and use thereof for adventitial or periaadventitial nerve ablation | |
US8709489B2 (en) | Emulsions containing arylboronic acids and medical articles made therefrom | |
Aktas et al. | Polymeric organo-hydrogels: novel biomaterials for medical, pharmaceutical, and drug delivery platforms | |
Jerbic | Biodegradable synthetic polymers and their application in advanced drug delivery systems (DDS) | |
JP2009545351A (en) | Release of active ingredient in subcutaneous graft beyond dilatation period | |
Marques et al. | PKPD of PLGA-PEG-PLGA Copolymeric Micelles | |
Rudra et al. | Poly [D, L-lactide-co-glycolide] microspheres as a delivery system of protein ovalbumin used as a model protein drug | |
US11197931B2 (en) | Liquid injectable copolymer | |
Naeem et al. | PF-127 based vildagliptin loaded polymeric hydrogels prepared by aqueous polymerization technique for treatment of diabetes mellitus | |
Brunacci et al. | Formulation of drug-loaded oligodepsipeptide particles with submicron size | |
KV et al. | Preparation of Poly-ε-Caprolactone Nanoparticles by Double Emulsion Solvent Evaporation Technique for Ocular Delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PENDANT BIOSCIENCES, INC., TENNESSEE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STEVENS, DAVID M.;RAGER-AGUIAR, DEAN JAMES;RUCKH, TIMOTHY TORDELLA;AND OTHERS;SIGNING DATES FROM 20190210 TO 20190211;REEL/FRAME:062970/0037 Owner name: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO, CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LE DEVEDEC, FRANTZ;ALLEN, CHRISTINE;REEL/FRAME:062970/0024 Effective date: 20190211 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |